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ABSTRACT 
Candida albicans is an opportunistic fungal pathogen responsible for localized as 
well as disseminated infections. C. albicans is the most commonly isolated specie from 
blood cultures, accounting for over 60% of all Candida isolates. The fungistatic drug 
fluconazole is the most widely used to treat fungal infections, thanks to its favorable bio-
availability and to its low toxicity. The frequent and widespread use of this antifungal has 
led to the outcome of drug resistant clinical isolates. Various drug resistance mechanisms 
are known that render C. albicans resistant to fluconazole, among those, the 
overexpression of efflux pumps, which extrude the drug out of the fungal cell, and the 
overexpression of the fluconazole target, the Erg11 enzyme. Overexpression of drug 
resistance genes is often associated to mutations in trans-acting transcription factors. The 
present study aimed at better understanding the role of known transcription factors 
involved in fluconazole resistance in C. albicans. In particular the role of TFs Mcm1 and 
Ada2 in resistance gene promoter activation has been evaluated. The transcription factors 
Mrr1 and Cap1 mediate MDR1 upregulation in response to inducing stimuli, and gain-of-
function mutations in Mrr1 or Cap1, which render the transcription factors hyperactive, 
result in constitutive MDR1 overexpression. The essential MADS box transcription factor 
Mcm1 also binds to the MDR1 promoter, but its role in inducible or constitutive MDR1 
upregulation is unknown. Using a conditional mutant in which Mcm1 can be depleted from 
the cells, the importance of Mcm1 for MDR1 expression was investigated. The results 
obtained indicated that Mcm1 was dispensable for MDR1 upregulation by H2O2, but 
required for full MDR1 induction by benomyl. A C-terminally truncated, hyperactive Cap1 
could upregulate MDR1 expression both in the presence and absence of Mcm1. In contrast, 
a hyperactive Mrr1 containing a gain-of-function mutation depended on Mcm1 to cause 
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MDR1 overexpression. These results demonstrate a differential requirement of the co-
regulator Mcm1 for Cap1- and Mrr1-mediated MDR1 upregulation. When activated by 
oxidative stress or a gain-of-function mutation, Cap1 could induce MDR1 expression 
independently of Mcm1, whereas Mrr1 required either Mcm1 or an active Cap1 to cause 
overexpression of the MDR1 efflux pump. 
Other transcription factors that mediate drug resistance gene regulation are Tac1, 
which regulates CDR1 and CDR2 expression, and Upc2, regulating ERG11 gene 
expression. Also in this case, gain-of-function mutations, which render these transcription 
factors hyperactive, result in constitutive overexpression of the target genes. 
Ada2 is part of the SAGA/ADA complex and has been shown to be recruited to 200 
promoters upstream of genes involved in different stress-response functions and metabolic 
processes. As for Mcm1, the importance of Ada2 for MDR1 expression was investigated, 
as well as for CDR2 and ERG11 expression. Ada2 was found to be dispensable for MDR1 
upregulation by H2O2, but required for MDR1 activation by hyperactive Cap1. When 
activated by benomyl or a gain-of-function mutation, Mrr1 induced MDR1 expression even 
better in the absence of Ada2. CDR2 expression by hyperactive Tac1 was facilitated in the 
presence of Ada2 and an opposite behaviour was observed when CDR2 expression was 
stimulated by the presence of fluphenazine in the medium. Finally, further experiments are 
required to better understand the role of Ada2 in the expression of ERG11.  
Overall, these findings provide a more detailed insight into the molecular 
mechanisms of drug resistance in this important human fungal pathogen. 
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1 INTRODUCTION 
1.1 Candida albicans 
The pathogenic fungus Candida albicans belongs to a genus composed of at least 
150 other species, of whom only a few are able to cause pathology in the human host [1]. 
Those can cause superficial as well as invasive fungal infections. Candida spp. are the 
most common cause of invasive or systemic mycoses, which have dramatically increased 
over the last 3 decades, particularly in intensive care units (ICUs), but in the outpatient or 
non-hospital setting as well. Over the last 2 decades, the proportion of non-C. albicans 
infections has raised, nevertheless C. albicans remains the most commonly isolated specie 
from blood cultures, accounting for over 60% of all Candida isolates. These trends have 
heightened interest in newer antifungal agents, such as those of the echinocandin class, that 
exhibit activity against a broad range of Candida spp., including non-albicans species with 
reduced sensitivity or resistance to traditional first-line agents such as fluconazole and 
amphotericin B [2]. 
One of the reasons that the consequences of invasive candidiasis or candidemia are 
so severe is that the diagnosis is often made late in the course of the infection, thereby 
delaying initiation of appropriate treatment. By the time a patient with invasive candidiasis 
develops a positive blood culture or a person at risk has yeast in his or her bloodstream, the 
patient is at high risk for metastatic infection of visceral organs that is associated with 
increased morbidity/mortality. Because definitive diagnosis of candidemia is often 
delayed, most patients with suspected systemic candidiasis are treated empirically (e.g. 
prior to culture results when the patient has early signs/symptoms that are not specific for 
the infection) or prophylactically (in high-risk patients before they show evidence of 
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disease). The potential drawback of this strategy is that many patients will receive 
unnecessary courses of antifungal therapy, and this can lead to increased risks for drug 
toxicity and antifungal resistance [2]. 
Different classes of antifungal drugs are currently available to treat fungal 
infections, each of them having a specific mode of action [3] [4] [5]. Among these, 5-
flucytosine inhibits fungal replication since it is a base analogue that is converted into 5-
fluorouracil by fungus-specific enzymes, cytosine deaminase and uracil 
phosphoribosyltransferase, and this leads to the formation of non functional DNA and 
RNA [6] [7] [8]. The polyenes target ergosterol by binding to it and creating a pore in the 
fungal membrane, eventually resulting in cell death [9]. The azoles (imidazoles, such as 
ketoconazole or miconazole, and triazoles such as fluconazole or voriconazole) interrupt 
the conversion of lanosterol to ergosterol resulting in a sterol-depleted membrane and in 
the accumulation of toxic compounds [10]. The echinocandins (caspofungin, micafungin, 
anidulafungin) work by inhibiting β-1,3-glucan synthase, thus preventing the synthesis of 
glucan, an important component of Candida cell wall [7] [11]. 
1.2 Antifungal drug resistance mechanisms 
1.2.1 5-Flucytosine 
Fungi can become resistant to each of the above mentioned antifungal drugs by 
specific mechanisms. 5-Flucytosine (5FC) is an antifungal drug that targets nucleic acid 
synthesis. The drug is fungus specific, since fungi and plants have a cytosine deaminase 
that converts 5FC into 5-fluorouracil, which is incorporated into DNA and RNA and 
inhibits cellular function and division. Mammalian cells do not have cytosine deaminase, 
and thus 5FC is not effective in these cells. 5FC is usually used in combination with 
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polyenes or other antifungal agents in the treatment of fungal infections since it has a high 
frequency of inducing drug resistance [5] [12]. 
Common resistance mutations include mutation of the cytosine deaminase, which 
converts 5FC to 5-fluorouracil, and mutation in the uracil phosphoribosyltransferase 
(UPRT), an enzyme important for nucleic acid synthesis. In a study performed by Hope et 
al. [13], primary resistance to 5FC in 25 C. albicans strains was investigated by identifying 
and sequencing the genes FCA1, FUR1, FCY21, and FCY22, which code for cytosine 
deaminase, UPRT, and two purine-cytosine permeases, respectively. These proteins are 
involved in pyrimidine salvage and 5FC metabolism. An association between a 
polymorphic nucleotide and resistance to 5FC was found within FUR1, where the 
substitution of cytosine for thymine at nucleotide position 301 results in the replacement of 
arginine with cysteine at amino acid position 101 in UPRT. Isolates that were homozygous 
for this mutation display increased levels of resistance to 5FC, whereas heterozygous 
isolates showed reduced susceptibility. A single resistant isolate, lacking the above 
polymorphism in FUR1, had a homozygous polymorphism FCA1 that results in a glycine-
to-aspartate substitution at position 28 in cytosine deaminase [13]. Another resistance 
mutation can occur in the cytosine permease, which imports cytosine and 5FC into the cell. 
Recently, mutation in the permease demonstrated a correlation between permease mutation 
and fluconazole uptake, perhaps the competition between 5FC and fluconazole [12] [14]. 
1.2.2 Polyenes 
The polyenes are a class of compounds with an amphipatic nature (one hydrophilic 
charged side of the molecule, and one hydrophobic uncharged side of the molecule). The 
polyenes target ergosterol, a sterol related to cholesterol, in fungal membranes. Ergosterol 
is the primary sterol in these fungal membranes, while cholesterol is the primary sterol in 
mammalian membranes. Polyenes work by binding to ergosterol and creating a pore that 
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allows small molecules to diffuse across the membrane, resulting in cell death. Hence, the 
polyenes are usually fungicidal at physiologic concentrations. There are two main 
polyenes: amphotericin B (AmB) and nystatin. AmB is the gold standard in the treatment 
of most fungal infections (Candida, Cryptococcus, and Aspergillus), especially in severe 
invasive infections where rapid response is needed. However, AmB has significant 
problems. Large doses are associated with nephrotoxicity, which limits its use. In addition, 
AmB is insoluble and so suspensions must be delivered intravenously. Use of nystatin is 
also limited by solubility issues. Both drugs can be used in a suspension for the treatment 
of oral fungal infections. Recently, lipid formulations of AmB have been developed which 
combine AmB with lipid structures to increase solubility and decrease toxicity. These 
formulations can be administered at higher AmB concentrations without toxicity, but they 
have a considerable expense [12]. 
Resistance to AmB has been identified in some clinical isolates, although the 
mechanism by which these isolates became resistant is not known. In addition, some 
laboratory strains with AmB resistance have been constructed [15]. Most of these isolates 
(clinical or laboratory) have a significant reduction of ergosterol in their plasma 
membrane, thus contributing to AmB resistance since the AmB target is absent [12]. 
1.2.3 Echinocandins 
The echinocandins are the newest category of antifungal drug. The drugs work by 
inhibiting β-1,3-glucan synthase in the plasma membrane of the fungal cells [16]. Glucan 
synthase is important for the production of glucan, an important component of the fungal 
cell wall [17] [18]. Caspofungin (Cancidas), the first class member, received FDA 
approval in 2002 for treatment of Candida and Aspergillus infections, although it is not 
effective for Cryptococcus infections. Micafungin and anidulafungin followed in 2005 and 
2006 respectively. Clinical resistance appears low with sporadic breakthrough cases 
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reported [19]. However, as patient exposure to echinocandin drugs broadens, the number 
of infecting strains with reduced susceptibility is expected to rise. Unfortunately, the 
relationship between reduced in vitro susceptibility to echinocandin drugs and clinical 
failure is ambiguous [20]. 
Early genetic studies by Myra Kurtz and Cameron Douglas (Merck Research Labs) 
with caspofungin in S. cerevisiae [21] [22] and C. albicans [23] indicated that Fks1, the 
major subunit of glucan synthase, is the presumed target of the echinocandins. These 
genetic studies suggested that target-site modification was a likely cause of reduced 
susceptibility. In fact, mutations that confer reduced echinocandin susceptibility in S. 
cerevisiae and C. albicans mapped to FKS1 [23] [24]. Clinical isolates of C. albicans 
displaying highly elevated MIC values for caspofungin were found to contain FKS1 
mutations. Specific amino acid substitutions helped define two regions termed “hot-spot” 1 
and 2 (HS1/HS2) that confer reduced susceptibility to caspofungin [25]. These regions are 
highly conserved amongst the Fks family [11].  
1.2.4 Azoles 
The azoles are the most important class of Ergosterol Biosynthesis Inhibitors (EBI). 
EBI are a diverse group of antifungal agents that include azoles, morpholines, 
thiocarbamates and allylamines. All of these drugs work by inhibiting the biosynthesis of 
ergosterol. Lack of ergosterol in the plasma membrane results in loss of membrane 
function and loss of fluidity that inhibits cell growth and division. Azoles work by 
inhibiting the product of the ERG11 gene, which demethylates lanosterol, an intermediate 
in the pathway [26]. Inhibition of Erg11 results in the replacement of ergosterol with 
methylated sterols in the plasma membrane. There are two classes of azole drugs. The 
imidazoles, including ketoconazole, miconazole, and clotrimazole, have limited use for 
treatment of systemic infections but are used commonly for localized, surface infections. 
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The triazoles, including fluconazole, voriconazole, and itraconazole, are now used 
primarily for systemic infections. Because of its ability to cross the blood-brain barrier, 
fluconazole remains the best treatment for Cryptococcus infections of the brain and is 
important for long term prophylaxis against reactivation of those infections [12]. 
Yeast and fungal pathogens have developed several mechanisms enabling 
resistance to the azoles class of antifungal. These mechanisms involve at least four 
different types of alterations. 
1.2.4.1 Alteration of antifungal transport enhanced ATP-dependent efflux 
Failure to accumulate azole antifungals has been identified as a cause of azole 
resistance in several post-treatment clinical fungal isolates. These isolates include yeast 
species such as C. albicans, C. glabrata, C. krusei, C. dubliniensis, and Cryptococcus 
neoformans. In azole-resistant isolates, genes encoding ATP binding cassette (ABC) 
transporters were upregulated compared to the corresponding azole-susceptible isolates. 
ABC transporter genes that have been identified as upregulated in azole-resistant isolates 
include CDR1 (for “Candida drug resistance 1”) and CDR2 in C. albicans, CdCDR1 in C. 
dubliniensis, a CDR1 homologue in C. tropicalis, CgCDR1 and CgCDR2 in C. glabrata, 
and CnAFR in C. neoformans. In Aspergillus fumigatus, itraconazole is able to induce an 
ABC transporter gene, atrF [12] [27] [28]. 
1.2.4.2 Alteration of antifungal transport by enhanced efflux dependent on the membrane 
proton gradient  
Besides upregulation of ABC transporter genes, a multidrug transporter gene 
CaMDR1 (for “multidrug resistance 1”), belonging to the family of major facilitators, is 
upregulated in some C. albicans azole-resistant yeast clinical isolates. In C. albicans and 
C. dubliniensis isolates with acquired azole resistance as a result of MDR1 upregulation, 
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deletion of CaMDR1 or CdMDR1 results in a sharp increase in azole susceptibility, thus 
supporting the involvement of this specific gene in azole resistance [29] [30]. Deletion of 
CaMDR1 in an azole-susceptible laboratory strain does not result in a significant increase 
in azole susceptibility, consistent with the fact that CaMDR1 is almost never expressed in 
this type of strain and more generally in azole-susceptible clinical isolates [12] [31]. 
1.2.4.3 Alteration of the target enzyme 
Azole resistance can also be the result of alterations in the target enzyme, Erg11, 
which demethylates lanosterol in the biosynthesis of ergosterol. Three types of alterations 
can occur with Erg11. First, the gene can be overexpressed. In one study, 35% of the 
resistant isolates had increased levels of ERG11 mRNA [32]. Second, the gene can be 
mutated so that azoles are less active against the enzyme. Point mutations have been 
identified in three “hot spot” regions in the enzyme, such as those surrounding the active 
site [33]. A small number of those mutations have been proven to cause resistance by 
alteration in Candida or expression in other systems. Third, a gene conversion can occur in 
which allelic differences in ERG11 are eliminated as resistance develops [34] [35]. It is 
postulated that this gene conversion occurs after one allele has been mutated to a resistant 
phenotype. Then drug pressure would select for a gene conversion event that resulted in 
the point mutation in both alleles of ERG11 [12]. 
1.2.4.4 Alteration of the ergosterol biosynthetic pathway 
Analysis of the sterol composition of some azole-resistant yeasts has revealed some 
alterations of enzymes involved in the ergosterol biosynthetic pathway. Accumulation of 
ergosta-7,22-dienol-3β-ol was observed in two separate azole-resistant C. albicans clinical 
isolates, which is a feature consistent with an absence of sterol Δ5,6-desaturase activity 
encoded by ERG3 [36]. Interestingly, azole resistance was coupled with resistance to 
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AmB, which was expected because of the absence of ergosterol. The role of ERG3 in azole 
resistance is suggested by the observation that exposure of yeast to azoles inhibits Erg11 
and thus results in accumulation of 14α-methylated sterols and 14α-methylergosta-
8,24(28)-dien-3β,6α-diol. Formation of this latter sterol metabolite is thought to be 
catalyzed by the ERG3 gene product, and thus inactivation of ERG3 suppresses toxicity 
and causes azole resistance. Loss-of-function mutations in ERG3 alleles from the C. 
albicans azole-resistant Darlington strain have been characterized [37]. The deletion of 
ERG3 in a C. albicans laboratory strain results in azole resistance [15], and thus one can 
assume that azole resistance in the Darlington strain is due to inactive ERG3 alleles. 
1.2.5 Transcriptional regulation of azole resistance 
Antifungal resistance is often associated with changes in the transcription of genes, 
some of them being involved directly in resistance. For example, azole resistance is linked 
to the upregulation of multidrug transporters belonging to the class of ABC transporters 
and major facilitators and also to the upregulation of ERG11 encoding the azole target. The 
molecular analysis of several azole-resistant isolates has revealed that these genes are in 
most cases not coordinately regulated but that each is regulated differentially [34] [35] [38] 
[39] [40]. This suggests that these genes are regulated by distinct regulatory pathways. 
1.2.5.1 Regulation of ABC transporters 
As mentioned above, CDR1 and CDR2 are major ABC transporters involved in 
azole resistance in Candida albicans. TAC1, a C. albicans transcription factor situated near 
the mating-type locus on chromosome 5, is necessary for the upregulation of the above 
mentioned ABC transporters mediating azole resistance [41]. It has been shown that a 
clinical azole-resistant strain that is homozygous at the mating-type locus contains a TAC1 
allele that is sufficient to confer fluconazole resistance to a laboratory strain lacking TAC1. 
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This type of allele was defined as “hyperactive” because it caused constitutive high 
expression of CDR1 and CDR2 in a tac1Δ/Δ mutant. In contrast, TAC1 alleles of the 
matched azole-susceptible clinical strain or of a laboratory strain, heterozygous at the 
mating-type locus, were not able to confer azole resistance to a tac1Δ/Δ mutant. These 
alleles were defined as “wild-type” alleles. A wild-type TAC1 allele also drives a high 
expression of CDR1/2 in response to inducers. For instance, exposure to fluphenazine 
results in a specific upregulation of CDR1 and CDR2 [42]. 
1.2.5.2 Regulation of Mdr1 efflux pump 
Constitutive overexpression of the MDR1 gene, which encodes a multidrug efflux 
pump of the major facilitator superfamily, is a frequent cause of resistance to fluconazole 
and other toxic compounds in clinical Candida albicans strains [32] [34] [38] [39] [43] 
[44]. 
MRR1, a zinc cluster transcription factor, is responsible for increased expression of 
MDR1 in drug-resistant clinical C. albicans isolates. Inactivation of MRR1 in drug resistant 
isolates abolished both MDR1 expression and multidrug resistance. Sequence analysis of 
the MRR1 alleles of matched drug-sensitive and drug-resistant C. albicans isolate pairs 
showed that the resistant isolates had become homozygous for MRR1 alleles that contained 
single nucleotide substitutions, such as a P683S change in one isolate or a G997V 
substitution in another isolate, but other substitutions have also been described [45]. The 
introduction of these mutated alleles into a drug-susceptible C. albicans strain resulted in 
constitutive MDR1 overexpression and multidrug resistance [46] [47]. 
Another transcription factor that has been identified as a regulator of MDR1 
expression is the CAP1 gene, which encodes for a bZip transcription factor. This TF has 
been shown to be involved in multidrug resistance and oxidative stress response in C. 
albicans [48]. The introduction of a hyperactive truncated allele of CAP1 (CAP1-TR) in the 
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yeast genome results in resistance of the cell to many toxic compounds such as 
fluconazole, cerulenin, brefeldin A. The hyper-resistant phenotype displayed in the 
transformants was found to correlate with the overexpression of a number of potential 
CAP1 transcriptional targets, including MDR1. 
MDR1 expression can also be induced in the presence of certain chemical 
compounds, such as benomyl or hydrogen peroxide [49] [50]. Deletion constructs of the 
MDR1 promoter helped identifying cis-acting elements in the MDR1 promoter responsible 
for induction by benomyl [51]. These elements were localized between -399/299 upstream 
of the start codon. The cis-acting elements responsible for MDR1 induction by peroxide 
were localized between -601/500 upstream of the start codon [49]. 
1.2.5.3 Regulation of Erg11 expression 
In Candida albicans, the zinc cluster transcription factor Upc2 has been shown to 
regulate the expression of ERG11 and other genes involved in ergosterol biosynthesis upon 
exposure to azole antifungals [52]. ERG11 encodes lanosterol demethylase, the target 
enzyme of this antifungal class. Overexpression of UPC2 reduces azole susceptibility, 
whereas its disruption results in hypersusceptibility to azoles and reduced accumulation of 
exogenous sterols. Overexpression of ERG11 leads to the increased production of 
lanosterol demethylase, which contributes to azole resistance in clinical isolates of C. 
albicans. UPC2 was found to be coordinately upregulated with ERG11 in a fluconazole-
resistant clinical isolate compared with a matched susceptible isolate from the same 
patient. Sequence analysis of the UPC2 alleles of these isolates revealed that the resistant 
isolate contained a single nucleotide substitution in one UPC2 allele that resulted in a 
G648D change in the encoded protein. Introduction of the mutated allele into a drug-
susceptible strain resulted in constitutive upregulation of ERG11 and increased resistance 
to fluconazole [45]. 
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ERG11 expression can also be upregulated by the presence of azoles and other 
sterol biosynthesis inhibitors. In vitro studies demonstrate that azoles are nonfungicidal, 
with continued growth at strain-dependent rates even at high azole concentrations. RNA 
analysis revealed that ERG11 expression in C. albicans is maximal during logarithmic-
phase growth and decreases as the cells approach stationary phase. Incubation with 
fluconazole, however, results in a two- to five fold increase in ERG11 RNA levels within 2 
to 3 hours, and this increase is followed by resumption of culture growth. ERG11 
upregulation also occurs following treatment with other azoles (itraconazole, ketoconazole, 
clotrimazole, and miconazole) [53]. 
1.2.5.4 Mcm1 
CaMCM1, a homologue of S. cerevisiae MCM1, is an essential gene of the MADS 
box transcription factor family involved in a variety of cellular processes, including 
chromatin remodelling, arginine response and mating as well as cell cycle regulation [54] 
[55]. In C. albicans, CaMCM1 is an essential gene as well. Its protein levels are crucial for 
the determination of cell morphology and are regulated by an autoregulatory feedback 
mechanism. Depletion of CaMcm1 leads to constitutive induction of hyphae. However, 
overexpression under specific conditions also results in enhanced hyphae formation. 
CaMcm1 acts as a mediator recruiting regulatory factors required for morphogenesis in C. 
albicans. In a study that has been published in 2006 by Riggle and Kumamoto [56], a 35-
bp MDR1 promoter element has been identified, termed the MDRE, that mediates high-
level MDR1 transcription. The MDRE promotes transcription in an orientation-
independent and dosage-dependent manner. Deletion of the MDRE in the full-lenght 
promoter does not abolish MDR1 trans-activation, indicating that elements upstream of the 
MDRE also contribute to transcription of MDR1 in overexpressing strains. Analysis of the 
MDRE sequence indicates that it contains an Mcm1 binding site. Electrophoretic mobility 
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shift analysis demonstrated that both wild-type, FLC-sensitive and MDR1 trans-activated 
FLC-resistant strains contain a factor that binds the MDRE. Depletion of Mcm1, by use of 
strain in which MCM1 expression in under the control of a regulated promoter [57], 
resulted in a loss of MDRE binding activity. Thus, the general transcription factor Mcm1 
participates in the regulation of MDR1 expression. 
1.2.5.5 Ada2 
The SAGA/ADA coactivator complex, which regulates numerous cellular 
processes by coordinating histone acetylation, is widely conserved in eukaryotes, and 
analysis of the Candida albicans genome identifies the components of this complex in the 
fungal pathogen [58]. Sellam et al. in 2009 investigated the multiple functions of 
SAGA/ADA in C. albicans by determining the genome-wide occupancy of Ada2 using 
chromatin immuneprecipitation (ChIP) [59]. Ada2 is recruited to 200 promoters upstream 
of genes involved in different stress-response functions and metabolic processes. 
Phenotypic and transcriptomic analysis of ΔΔada2 mutant showed that Ada2 is required 
for the responses to oxidative stress, as well as to treatments with tunicamycin and 
fluconazole. Ada2 recruitment to the promoters of oxidative resistance genes is mediated 
by the transcription factor Cap1, and coactivator function were also established for Gal4, 
which recruits Ada2 to the promoters of glycolysis and pyruvate metabolism genes. Co-
occupancy of Ada2 and the drug resistance regulator Mrr1 on the promoters of core 
resistance genes characterizing drug resistance in clinical strains was also demonstrated. 
Ada2 recruitment to the promoters of these genes were shown to be completely dependent 
on Mrr1. Furthermore, ADA2 deletion causes a decrease in H3K9 acetylation levels of 
target genes, thus highlighting its importance for histone acetyl transferase activity [59]. 
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1.3 Molecular tools available for Candida albicans 
Genetic manipulation of C. albicans has been hindered by some of its own 
attributes. The construction of mutant strains is relatively laborious in comparison to S. 
cerevisiae due to the lack of an exploitable sexual cycle and the diploid nature of C. 
albicans. The expression of heterologous genes, like reporter genes, is also problematic 
because of the non-canonical decoding of the CUG codon [60] [61]. Until recently, genetic 
engineering in C. albicans largely depended on the use of auxotrophic strains because no 
dominant markers were available for the selection of transformants. Despite these 
limitations, powerful molecular methods for transformation, gene disruption and gene 
expression have been developed in recent years [60] [61]. This was facilitated by the recent 
availability of the complete C. albicans genome sequence. An optimized tool for gene 
disruption has been described by Reuß et al. in 2004 which has been used in this study 
[62]. 
1.3.1 Transformation vectors 
The use of episomal plasmids results in relatively high transformation frequencies 
because they do not require a homologous recombination event. However, these plasmids 
need to contain one of the three autonomous replicating sequences identified for C. 
albicans. In most cases, transformants obtained by this method will contain both episomal 
and integrated plasmid copies in variable numbers [63]. This genetic variability is not 
conducive to accurate molecular manipulation. Specific integration vectors that allow high-
frequency transformation into neutral chromosomal sites have been described [64] [65] 
[66]. These vectors rely on the homologous recombination between a C. albicans gene or a 
gene fragment present in the plasmid and its chromosomal counterpart. Integration 
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frequency is improved dramatically by linearising the plasmid within the region of 
homology to generate recombinogenic ends [63].  
1.3.2 Gene inactivation 
In general, specific deletions of C. albicans genomic regions are constructed by 
using a disruption cassette that contains a selectable marker sequence and flanking regions 
of homology to the target locus that promote genomic integration by homologous 
recombination [63]. The URA-blaster strategy was the most extensively used method for 
the sequential disruption of both copies of a gene in C. albicans [67]. This strategy is based 
on a hisG-URA-hisG cassette, which contains the C. albicans URA3 gene flanked by direct 
repeats of Salmonella typhimurium hisG. Insertion is achieved by homologous 
recombination between the gene-specific regions flanking this disruption cassette and the 
chromosomal copy of the gene. Subsequent intrachromosomal homologous recombination 
between the hisG repeats results in the loss of the URA3 marker. These Ura-revertants can 
be selected on medium containing 5-fluoroorotic acid (5-FOA). The same cassette can then 
be used to inactivate the second copy of the gene [67] [68]. More recently, several 
observations revealed that the use of the URA3 marker in gene disruptions may lead to 
inaccurate interpretation of the results. Proper control strains expressing the URA3 marker 
from the same locus as the mutant strains are required to exclude these “URA3-effects” 
[69] [70] [71] [72]. 
A Polymerase Chain Reaction-based disruption method employs long 
oligonucleotides with homology to the target gene [73] [74]. These oligonucleotides are 
used as primers to amplify the selectable marker from a vector, in order to create a 
disruption cassette comprising the selectable marker flanked by short regions of homology 
to the target locus. The disruption cassette is transformed directly into C. albicans. This 
strategy is quicker than the URA-blaster method because it does not require the 
 
15 Introduction, 
construction of the disruption cassette by cloning. However, a double auxotrophic strain is 
required because each allele must be disrupted with a different marker, since they cannot 
be recycled [68]. Alternative gene disruption methods have been developed more recently 
to allow marker recycling, make the process less time-consuming and avoid the use of 5-
FOA, which might induce chromosome alterations [75]. In the URA-flipper method the 
URA3 marker becomes excised by the Flp recombinase, which is also part of the disruption 
cassette [76]. The Cre-Lox system also relies on a recombinase, the site-specific (Cre) 
recombinase, to excise the selectable markers and allow further deletions of other genes in 
the same strain [77].  
The SAT1 flipping method relies on the use of a cassette that contains a dominant 
nourseothricin resistance marker (caSAT1) for the selection of integrative transformants 
and a C. albicans-adapted FLP gene that allows the subsequent excision of the cassette, 
which is flanked by FLP target sequences, from the genome [62]. Two rounds of 
integration/excision generate homozygous mutants that differ from the wild-type parent 
strain only by the absence of the target gene, and reintegration of an intact gene copy for 
complementation of mutant phenotypes is performed in the same way. Transformants are 
obtained after only one day of growth on a selective medium, and integration into the 
target locus occurs with high specificity after adding homologous flanking sequences on 
both sides of the cassette. FLP-recombinase is put under the control of the MAL2 promoter 
and FLP-mediated excision of the SAT1 flipper cassette can be achieved by simply 
growing the transformants for a few hours in medium containing maltose without selective 
pressure, and nourseothricin-sensitive (Nou
s
) derivatives can easily be identified by their 
slower growth on indicator plates containing a low concentration of nourseothricin. 
Another way of inducing the expression of the FLP-recombinase is by putting this gene 
under the control of another inducible promoter, PSAP2. This method is less “leaky” than the 
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previous one since the PMAL2 can be induced also in complete medium not containing 
maltose. In this way, the FLP-recombinase expression can be induced by the presence of 
BSA in the growth medium. 
Fig. 1 shows a schematic model of the SAT1 flipper cassette used in this study. 
 
Fig. 1. Structure of the SAT1 flipper cassette. 
The C. albicans-adapted FLP gene (caFLP) is represented by the red arrow, the 
nourseothricin resistance marker (caSAT1) by the blue arrow, the SAP2 promoter 
(PSAP2) by the bent green arrow, and the transcription termination sequence of the C. 
albicans ACT1 gene (ACT1t) by the filled circle. The 34-bp FLP recombination target 
sequences (FRT, black arrows) (5‟-GAA GTT CCT ATA CTT TCT AGA GAA TAG 
GAA CTT C-3‟) flanking the cassette are not drawn to scale. The figure has been 
modified from Reuß et al. [62]. 
1.3.3 Reporter genes 
Reporter genes are useful tools to study gene regulation, although they do not 
necessarily reflect transcript stability of the gene of interest [60] [63]. The LAC4 gene of 
the yeast Kluveromyces lactis, which encodes β-galactosidase, was the first functional 
heterologous reporter gene for C. albicans [78]. The moderate sensitivity initially achieved 
with colorimetric substrates was dramatically increased using a bioluminescent substrate 
[79]. A second reporter system based on the enzymatic activity of the β-galactosidase was 
developed by Uhl et al. in 2001 [80]. In this case, the lacZ gene of Streptococcus 
thermophilus was cloned downstream of three different promoters, a constitutive one and 
FRT FRTPSAP2
5‟ locus X 3‟ locus X
caFLP caSAT1ACT1t
locus X
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two inducible ones. Expression was readily detected in liquid assays using permeabilised 
cells and in situ colorimetric assays of colonies growing on plates. The luciferase gene 
from the sea pansy Renilla reniformis (RrLUC) does not contain CTG codons, and thus has 
been exploited as a useful reporter gene in C. albicans [81]. The bioluminescence based- 
assay proved an effective tool to study the activity of inducible, constitutive and phase-
specific (white or opaque) promoters. However, the efficiency of this system with intact 
cells is significantly lower than with protein extracts. Reporter systems based on modified 
versions of the green fluorescent protein (GFP) gene from the jellyfish Aequorea victoria 
are also available [82] [83]. They have been genetically engineered to replace the non-
canonical CTG serine codon for the TTG leucine codon and to carry mutations in the 
chromophore that enhance GFP fluorescence. These yEGFP (yeast enhanced GFP) genes 
offer major advantages in comparison to the β-galactosidase and luciferase enzymatic 
systems: no cofactors are required for the expression of GFP and the resulting fluorescence 
can be detected in living organisms, even at the level of single cells [84] [85]. This makes 
yEGFP an optimal reporter for studying the sub-cellular localization of a protein of interest 
[60]. More recently, cassettes for the PCR-mediated construction of green, yellow and 
cyan fluorescent protein fusions have also been developed [86].  
1.4 Aims of the study 
Fluconazole is the most widely used antimycotic to treat infections caused by C. 
albicans, the most common agent of human fungal infections, but the frequent and 
widespread use of this drug has caused an increased frequency of drug resistant clinical C. 
albicans strains. The present study was aimed to investigate new aspects of the underlying 
mechanisms that lead to fluconazole resistance in C. albicans. Previous studies have 
illustrated that common fluconazole resistance mechanisms in C. albicans are the 
overexpression of efflux pumps (such as MDR1, CDR1 and CDR2) or the overexpression 
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of the target gene ERG11, which are regulated by known transcription factors (CAP1, 
MRR1, TAC1, UPC2). Recently, new transcription factors (TFs), MCM1 and ADA2 have 
been shown to be involved in drug resistance gene regulation. On this ground, the present 
study was focused to define the role of those two transcription factors in the azole 
resistance. To this aim, MCM1 conditional mutants [57] and ADA2 knock-out mutants, 
constructed in this study, were used to analyze the expression of drug resistance related 
genes in response to inducing chemicals. In addition, expression of drug resistance related 
genes has also been evaluated in MCM1 or ADA2 mutants containing hyperactive 
transcription factors alleles. 
The present PhD project was carried out at the “Dipartimento di Biologia, sezione 
di Microbiologia” of the University of Pisa, Via San Zeno 35-39, under the supervision of 
Prof. ssa Sonia Senesi, and at the mycology unit of the “Institut für Molekulare 
Infektionsbiologie”, Josef-Schneider Straße 2, Bau D15, 97080 Würzburg, under the 
supervision of Prof. Joachim Morschhäuser. 
  
2 MATERIALS AND METHODS 
For all microbiology and molecular biology procedures standard protocols were 
followed from Sambrook et al., (1989) [87] or Asubel et al., (1989) [88] with minor 
modifications.  
All solutions and media were made in double distilled and distilled water, 
respectively. All solutions and media were sterilized by autoclaving or filter sterilized by 
passing through a 0.22 micron Millipore filter. 
2.1 Bacterial strain 
Escherichia coli K12: E. coli strain DH5α (F-, endA1, hsdR17 [rk
-
, mk
-
], supE44, 
thi-1, recA1, gyrA96, relA1, Δ[argF-lac]U169, λ-, Φ80dlacZΔM15) (Bethesda Research 
Laboratories, 1986) was used for bacterial cloning experiments. 
2.2 Primers 
Details of primers used in this study are shown in Table 1. Primers were obtained 
from MWG (Ebersberg, Germany). 
Table 1. List of primers used in this study 
Primer 
name 
Sequence (5'-3') Gene 
Gene 
sequences 
Introduced 
restriction 
sites/ position 
ACT1RT AGTGTGACATGGATGTTAGAAAAGAATTATACGG ACT1 +1512 +1545  
ACT2RT ACAGAGTATTTTCTTTCTGGTGGAGCA ACT1 +1677 +1651  
ADA2-3 GGGATGGTGTTCTCGAGGGGTAAATGTAG ADA2 +1317 +1344 XhoI +1328 
ADA2-4 GATCGGGCCCTACTTGATCGGTCATACTGGAGC ADA2 +1753 +1721 ApaI +1748 
ADA2-5 AACCTAGCAAACGAGCTCACGTGATGTAAGTG ADA2 -529 -498 SacI -513 
ADA2-6 GATAATCATGCCGCGGTTTATGATCTCCAG ADA2 +160 +131 SacII +148 
ADA2-7 GCAGGATTGACTACTGGAGCTCATAAACCATG ADA2 +118 +149 SacI +138 
ADA2-8 GGTAATGGTATATTTTTCCGCGGTTCTAATCGTTC ADA2 +452 +418 SacII +433 
ADA2-9 CCAAACACCAGGATTCTCGAGTGGTAATTCTT ADA2 +987 +1018 XhoI +1002 
ADA2-10 CTGAGAACACGGGCCCATATGCACAAA ADA2 +1332 +1306 ApaI +1321 
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Primer 
name 
Sequence (5'-3') Gene 
Gene 
sequences 
Introduced 
restriction 
sites/ position 
ADA2-11 ATATGAGCTCGGGCCCACTCACGTGATGTAAGTGC ADA2 -518 -497 SacI-ApaI 
ADA2-12 CTCCATCTCAACCGCGGCCAGAAGTATTGCC ADA2 +1902 +1872 SacII +1889 
CDR2-5 AGATGGTACCAGGTAGTGATAGTTAACACACC CDR2 -464 -433 KpnI -456 
CDR2-6 ATATGTCGACATTGTATGTGTTAATTAGTGAAATA CDR2 +2 -33 SalI -8 
EFB1A ATTGAACGAATTCTTGGCTGAC EF1B +42 +63  
EFB1B CATCTTCTTCAACAGCAGCTTG EF1B +960 +939  
MDR5RT ATTTGTTCAGATCAGTCATTGCTTCAGTGT MDR1 +1499 +1528  
MDR6RT GGTCCGTTCAAGTAAAACAAAACTGGAATA MDR1 +1661 +1632  
Restriction sites introduced into the primers are underlined. 
2.3 Plasmids 
The following abbreviations are used in the description of plasmids: caFLP: C. 
albicans-adapted FLP gene encoding the site specific recombinase FLP; caSAT1: C. 
albicans-adapted nourseothricin resistance marker (dominant selection marker); FRT: 
(FLP-recognition target) minimal recombination target sites of the FLP recombinase; 
GFP: Green fluorescent protein gene; Px: Promoter of the given gene (X) ; Ptet: rtTA-
dependent promoter; ACT1t: Transcription termination sequence of the actin (ACT1) gene. 
Table 2. Plasmids used in this study 
Plasmids Relevant insert Reference 
Plasmids used for the MCM1 study 
pCAP1R1 
[5'CAP1ΔC333-ACT1t-FRT-PMAL2-caFLP-ACT1t-caSAT1-FRT-3'CAP1]- fragment 
for introduction of hyperactive CAP1 allele 
Schubert et al., 
submitted 
pMPG2S 
[3'ACT1-PMDR1-GFP-ACT1t-caSAT1-PACT1]- fragment for MDR1 promoter 
analysis, integration on ACT1 promoter 
Morschhäuser et 
al., 2007 [46] 
pMRR1R3 
[MRR1P683S-ACT1t-FRT-PMAL2-caFLP-ACT1t-caSAT1-FRT-3'MRR1]- fragment 
for introduction of hyperactive MRR1 allele 
Schubert et al., 
submitted 
Plasmids used for the ADA2 study 
pADA2K1 
[ADA2-FRT-PSAP2-1-caFLP-ACT1t-caSAT1-FRT-3'ADA2]- fragment for gene 
reintegration 
This study 
pADA2M1 [5'CAP1-FRT-PSAP2-1-caFLP-ACT1t-caSAT1-FRT-3'ADA2]- fragment This study 
pADA2M2 
[5'ADA2-FRT-PSAP2-1-caFLP-ACT1t-caSAT1-FRT-3'ADA2]- fragment for gene 
deletion (allele 1) 
This study 
pADA2M3 [5'ADA2-FRT-PSAP2-1-caFLP-ACT1t-caSAT1-FRT-3'ADA2]- fragment This study 
pADA2M4 
[5'ADA2-FRT-PMAL2-caFLP-ACT1t-caSAT1-FRT-3'ADA2]- fragment for gene 
deletion (allele 2) 
This study 
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Plasmids Relevant insert Reference 
pCAP1R1 
[5'CAP1ΔC333- ACT1t -FRT-PMAL2-caFLP-ACT1t-caSAT1-FRT-3'CAP1]- 
fragment for introduction of hyperactive CAP1 allele 
Schubert et al., 
submitted 
pCDR2G3 [PCDR2-GFP-ACT1t-caSAT1-3'CDR2]- fragment for CDR2 promoter analysis This study 
pERG11G2 [PERG11-GFP-ACT1t-caSAT1-3'ERG11]- fragment for ERG11 promoter analysis 
Heilmann et al., 
2010 [89] 
pMDR1G3 [PMDR1-GFP-ACT1t-caSAT1-3'MDR1]- fragment for MDR1 promoter analysis Morschhäuser lab 
pMRR1R3 
[MRR1P683S-ACT1t-FRT-PMAL2-caFLP-ACT1t-caSAT1-FRT-3'MRR1]- fragment 
for introduction of hyperactive MRR1 allele 
Schubert et al., 
submitted 
pTAC1R3 
[3'TAC1G980E-ACT1t-FRT-PMAL2-caFLP-ACT1t-caSAT1-FRT-3'TAC1]- fragment 
for introduction of TAC1 hyperactive allele  
Morschhäuser lab 
pUPC2R1 
[UPC2G648D-ACT1t-FRT-PMAL2-caFLP-ACT1t-caSAT1-FRT-3'UPC2]- fragment 
for introduction of UPC2 hyperactive allele 
Heilmann et al., 
2010 [89] 
 
2.4 C. albicans strains 
Parental and mutant Candida albicans strains used in this study are listed in Table 
3. Some mutants used in this study where already present in the collection of Prof. 
Morschhäuser‟s group. MRcan42 and MRcan43 where kindly provided by Prof. Steffen 
Rupp (University of Stuttgart, Germany) and SC5314 is the Candida albicans reference 
strain. 
Table 3. Strains used in this study 
Strain Parent Relevant genotype Reference 
SC5314  Wild-type reference strain 
Gillum et al., 
1984 [90] 
SCMPG2A SC5314 ACT1/act1::PMDR1-GFP-caSAT1 
Morschhäuser et 
al., 2007 [46] 
SCMPG2B SC5314 ACT1/act1::PMDR1-GFP-caSAT1 
Morschhäuser et 
al., 2007 [46] 
MRcan42 SC531 pTR-MCM1-myc/mcm1Δ 
Rottmann et al., 
2003 [57] 
MRcan43 SC5314 pTR-MCM1/MCM1-myc 
Rottmann et al., 
2003 [57] 
can42MPG2A MRcan42 ACT1/act1::PMDR1-GFP-caSAT1 this study 
can42MPG2B MRcan42 ACT1/act1::PMDR1-GFP-caSAT1 this study 
can43MPG2A MRcan43 ACT1/act1::PMDR1-GFP-caSAT1 this study 
can43MPG2B MRcan43 ACT1/act1::PMDR1-GFP-caSAT1 this study 
can42MRR1R31A MRcan42 MRR1/MRR1P683S-SAT1-FLIP this study 
can42MRR1R31B MRcan42 MRR1/MRR1P683S-SAT1-FLIP this study 
can42MRR1R32A can42MRR1R31A MRR1/MRR1P683S-FRT this study 
can42MRR1R32B can42MRR1R31B MRR1/MRR1P683S-FRT this study 
can42MRR1R33A can42MRR1R32A MRR1P683S-SAT1-FLIP/MRR1P683S-FRT this study 
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Strain Parent Relevant genotype Reference 
can42MRR1R33B can42MRR1R32B MRR1P683S-SAT1-FLIP/MRR1P683S-FRT this study 
can42MRR1R34A can42MRR1R33A MRR1P683S-FRT/MRR1P683S-FRT this study 
can42MRR1R34B can42MRR1R33B MRR1P683S-FRT/MRR1P683S-FRT this study 
can43MRR1R31A MRcan43 MRR1/MRR1P683S-SAT1-FLIP this study 
can43MRR1R31B MRcan43 MRR1/MRR1P683S-SAT1-FLIP this study 
can43MRR1R32A can43MRR1R31A MRR1/MRR1P683S-FRT this study 
can43MRR1R32B can43MRR1R31B MRR1/MRR1P683S-FRT this study 
can43MRR1R33A can43MRR1R32A MRR1P683S-SAT1-FLIP/MRR1P683S-FRT this study 
can43MRR1R33B can43MRR1R32B MRR1P683S-SAT1-FLIP/MRR1P683S-FRT this study 
can43MRR1R34A can43MRR1R33A MRR1P683S-FRT/MRR1P683S-FRT this study 
can43MRR1R34B can43MRR1R33B MRR1P683S-FRT/MRR1P683S-FRT this study 
can42CAP1R11A MRcan42 CAP1ΔC333-SAT1-FLIP/CAP1-2 this study 
can42CAP1R11B MRcan42 CAP1-1/CAP1ΔC333-SAT1-FLIP this study 
can42CAP1R12A can42CAP1R11A CAP1ΔC333-FRT/CAP1-2 this study 
can42CAP1R12B can42CAP1R11B CAP1-1/CAP1ΔC333-FRT this study 
can42CAP1R13A can42CAP1R12A CAP1ΔC333-FRT/CAP1ΔC333-SAT1-FLIP this study 
can42CAP1R13B can42CAP1R12B CAP1ΔC333-SAT1-FLIP/CAP1ΔC333-FRT this study 
can42CAP1R14A can42CAP1R13A CAP1ΔC333-FRT/CAP1ΔC333-FRT this study 
can42CAP1R14B can42CAP1R13B CAP1ΔC333-FRT/CAP1ΔC333-FRT this study 
can43CAP1R11A MRcan43 CAP1-1/CAP1ΔC333-SAT1-FLIP this study 
can43CAP1R11B MRcan43 CAP1-1/CAP1ΔC333-SAT1-FLIP this study 
can43CAP1R12A can43CAP1R11A CAP1-1/CAP1ΔC333-FRT this study 
can43CAP1R12B can43CAP1R11B CAP1-1/CAP1ΔC333-FRT this study 
can43CAP1R13A can43CAP1R12A CAP1ΔC333-SAT1-FLIP/CAP1ΔC333-FRT this study 
can43CAP1R13B can43CAP1R12B CAP1ΔC333-SAT1-FLIP/CAP1ΔC333-FRT this study 
can43CAP1R14A can43CAP1R13A CAP1ΔC333-FRT/CAP1ΔC333-FRT this study 
can43CAP1R14B can43CAP1R13B CAP1ΔC333-FRT/CAP1ΔC333-FRT this study 
SCADA2M1A SC5314 ada2Δ::SAT1-FLIP/ADA2 this study 
SCADA2M1B SC5314 ada2Δ::SAT1-FLIP/ADA2 this study 
SCADA2M2A SCADA2M1A ada2Δ::FRT/ADA2 this study 
SCADA2M2B SCADA2M1B ada2Δ::FRT/ADA2 this study 
SCADA2M3A SCADA2M2A ada2Δ::FRT/ada2Δ::SAT1-FLIP this study 
SCADA2M3B SCADA2M2B ada2Δ::FRT/ada2Δ::SAT1-FLIP this study 
SCADA2M4A SCADA2M3A ada2Δ::FRT/ada2Δ::FRT this study 
SCADA2M4B SCADA2M3B ada2Δ::FRT/ada2Δ::FRT this study 
SCADA2MK1A SCADA2M4A ADA2::SAT1-FLIP/ada2Δ::FRT this study 
SCADA2MK1B SCADA2M4B ADA2::SAT1-FLIP/ada2Δ::FRT this study 
SCADA2MK2A SCADA2MK1A ADA2::FRT/ada2Δ::FRT this study 
SCADA2MK2B SCADA2MK1B ADA2::FRT/ada2Δ::FRT this study 
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Strain Parent Relevant genotype Reference 
SCΔada2CG3A SCADA2M4A CDR2/cdr2::PCDR2-GFP-caSAT1 this study 
SCΔada2CG3B SCADA2M4B CDR2/cdr2::PCDR2-GFP-caSAT1 this study 
SCΔada2EG2A SCADA2M4A ERG11/erg11::PERG11-GFP-caSAT1 this study 
SCΔada2EG2B SCADA2M4B ERG11/erg11::PERG11-GFP-caSAT1 this study 
SCΔada2MG3A SCADA2M4A MDR1/mdr1::PMDR1-GFP-caSAT1 this study 
SCΔada2MG3B SCADA2M4B MDR1/mdr1::PMDR1-GFP-caSAT1 this study 
SCΔada2CAP1R11A SCADA2M4A CAP1ΔC333-SAT1-FLIP/CAP1-2 this study 
SCΔada2CAP1R11B SCADA2M4B CAP1-1/CAP1ΔC333-SAT1-FLIP this study 
SCΔada2CAP1R12A SCΔada2CAP1R11A CAP1ΔC333-FRT/CAP1-2 this study 
SCΔada2CAP1R12B SCΔada2CAP1R11B CAP1-1/CAP1ΔC333-FRT this study 
SCΔada2CAP1R13A SCΔada2CAP1R12A CAP1ΔC333-FRT/CAP1ΔC333-SAT1-FLIP this study 
SCΔada2CAP1R13B SCΔada2CAP1R12B CAP1ΔC333-SAT1-FLIP/CAP1ΔC333-FRT this study 
SCΔada2CAP1R14A SCΔada2CAP1R13A CAP1ΔC333-FRT/CAP1ΔC333-FRT this study 
SCΔada2CAP1R14B SCΔada2CAP1R13B CAP1ΔC333-FRT/CAP1ΔC333-FRT this study 
SCΔada2CAP1R14MG3A SCΔada2CAP1R14A MDR1/mdr1::PMDR1-GFP-caSAT1 this study 
SCΔada2CAP1R14MG3B SCΔada2CAP1R14B MDR1/mdr1::PMDR1-GFP-caSAT1 this study 
SCΔada2MRR1R31A SCADA2M4A MRR1P683S-SAT1-FLIP/MRR1 this study 
SCΔada2MRR1R31B SCADA2M4B MRR1P683S-SAT1-FLIP/MRR1 this study 
SCΔada2MRR1R32A SCΔada2MRR1R31A MRR1P683S-FRT/MRR1 this study 
SCΔada2MRR1R32B SCΔada2MRR1R31B MRR1P683S-FRT/MRR1 this study 
SCΔada2MRR1R33A SCΔada2MRR1R32A MRR1P683S-FRT/MRR1P683S-SAT1-FLIP this study 
SCΔada2MRR1R33B SCΔada2MRR1R32B MRR1P683S-FRT/MRR1P683S-SAT1-FLIP this study 
SCΔada2MRR1R34A SCΔada2MRR1R33A MRR1P683S-FRT/MRR1P683S-FRT this study 
SCΔada2MRR1R34B SCΔada2MRR1R33B MRR1P683S-FRT/MRR1P683S-FRT this study 
SCΔada2MRR1R34MG3A SCΔada2MRR1R34A MDR1/mdr1::PMDR1-GFP-caSAT1 this study 
SCΔada2MRR1R34MG3B SCΔada2MRR1R34B MDR1/mdr1::PMDR1-GFP-caSAT1 this study 
SCΔada2TAC1R31A SCADA2M4A TAC1G980E-SAT1-FLIP/TAC1-2 this study 
SCΔada2TAC1R31B SCADA2M4B TAC1-1/TAC1G980E-SAT1-FLIP this study 
SCΔada2TAC1R32A SCΔada2TAC1R31A TAC1G980E-FRT/TAC1-2 this study 
SCΔada2TAC1R32B SCΔada2TAC1R31B TAC1-1/TAC1G980E-FRT this study 
SCΔada2TAC1R33A SCΔada2TAC1R32A TAC1G980E-FRT/TAC1G980E-SAT1-FLIP this study 
SCΔada2TAC1R33B SCΔada2TAC1R32B TAC1G980E-SAT1-FLIP/TAC1G980E-FRT this study 
SCΔada2TAC1R34A SCΔada2TAC1R33A TAC1G980E-FRT/TAC1G980E-FRT this study 
SCΔada2TAC1R34B SCΔada2TAC1R33B TAC1G980E-FRT/TAC1G980E-FRT this study 
SCΔada2TAC1R34CG3A SCΔada2TAC1R34A CDR2/cdr2::PCDR2-GFP-caSAT1 this study 
SCΔada2TAC1R34CG3B SCΔada2TAC1R34B CDR2/cdr2::PCDR2-GFP-caSAT1 this study 
SCΔada2UPC2R11A SCADA2M4A UPC2G648D-SAT1-FLIP/UPC2 this study 
SCΔada2UPC2R11B SCADA2M4B UPC2G648D-SAT1-FLIP/UPC2 this study 
SCΔada2UPC2R12A SCΔada2UPC2R11A UPC2G648D-FRT/UPC2 this study 
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Strain Parent Relevant genotype Reference 
SCΔada2UPC2R12B SCΔada2UPC2R11B UPC2G648D-FRT/UPC2 this study 
SCΔada2UPC2R13A SCΔada2UPC2R12A UPC2G648D-FRT/UPC2G648D-SAT1-FLIP this study 
SCΔada2UPC2R13B SCΔada2UPC2R12B UPC2G648D-FRT/UPC2G648D-SAT1-FLIP this study 
SCΔada2UPC2R14A SCΔada2UPC2R13A UPC2G648D-FRT/UPC2G648D-FRT this study 
SCΔada2UPC2R14B SCΔada2UPC2R13B UPC2G648D-FRT/UPC2G648D-FRT this study 
SCΔada2UPC2R14EG2A SCΔada2UPC2R14A ERG11/erg11::PERG11-GFP-caSAT1 this study 
SCΔada2UPC2R14EG2B SCΔada2UPC2R14B ERG11/erg11::PERG11-GFP-caSAT1 this study 
SCCG3A SC5314 CDR2/cdr2::PCDR2-GFP-caSAT1 this study 
SCCG3B SC5314 CDR2/cdr2::PCDR2-GFP-caSAT1 this study 
SCEG2A SC5314 ERG11/erg11::PERG11-GFP-caSAT1 
Heilmann et al., 
2010 [89] 
SCEG2B SC5314 ERG11/erg11::PERG11-GFP-caSAT1 
Heilmann et al., 
2010 [89] 
SCMG3A SC5314 MDR1/mdr1::PMDR1-GFP-caSAT1 Morschhäuser lab 
SCMG3B SC5314 MDR1/mdr1::PMDR1-GFP-caSAT1 Morschhäuser lab 
SCCAP1R12A SC5314 CAP1ΔC333-FRT/CAP1-2 
Schubert et al., in 
revision 
SCCAP1R12B SC5314 CAP1-1/CAP1ΔC333-FRT 
Schubert et al., in 
revision 
SCCAP1R14A SCCAP1R12A CAP1ΔC333-FRT/CAP1ΔC333-FRT 
Schubert et al., in 
revision 
SCCAP1R14B SCCAP1R12B CAP1ΔC333-FRT/CAP1ΔC333-FRT 
Schubert et al., in 
revision 
SCCAP1R14MG3A SCCAP1R14A MDR1/mdr1::PMDR1-GFP-caSAT1 this study 
SCCAP1R14MG3B SCCAP1R14B MDR1/mdr1::PMDR1-GFP-caSAT1 this study 
SCMRR1R32A SC5314 MRR1P683S-FRT/MRR1 
Schubert et al., in 
revision 
SCMRR1R32B SC5314 MRR1P683S-FRT/MRR1 
Schubert et al., in 
revision 
SCMRR1R34A SCMRR1R32A MRR1P683S-FRT/MRR1P683S-FRT 
Schubert et al., in 
revision 
SCMRR1R34B SCMRR1R32B MRR1P683S-FRT/MRR1P683S-FRT 
Schubert et al., in 
revision 
SCMRR1R34MG3A SCMRR1R34A MDR1/mdr1::PMDR1-GFP-caSAT1 this study 
SCMRR1R34MG3B SCMRR1R34B MDR1/mdr1::PMDR1-GFP-caSAT1 this study 
SCTAC1R32A SC5314 TAC1G980E-FRT/TAC1-2 Morschhäuser lab 
SCTAC1R32B SC5314 TAC1-1/TAC1G980E-FRT Morschhäuser lab 
SCTAC1R34A SCTAC1R32A TAC1G980E-FRT/TAC1G980E-FRT Morschhäuser lab 
SCTAC1R34B SCTAC1R32B TAC1G980E-FRT/TAC1G980E-FRT Morschhäuser lab 
SCTAC1R34CG3A SCTAC1R34A CDR2/cdr2::PCDR2-GFP-caSAT1 this study 
SCTAC1R34CG3B SCTAC1R34B CDR2/cdr2::PCDR2-GFP-caSAT1 this study 
SCUPC2R12A SC5314 UPC2G648D-FRT/UPC2 
Heilmann et al., 
2010 [89] 
SCUPC2R12B SC5314 UPC2G648D-FRT/UPC2 
Heilmann et al., 
2010 [89] 
SCUPC2R14A SCUPC2R12A UPC2G648D-FRT/UPC2G648D-FRT 
Heilmann et al., 
2010 [89] 
SCUPC2R14B SCUPC2R12B UPC2G648D-FRT/UPC2G648D-FRT 
Heilmann et al., 
2010 [89] 
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Strain Parent Relevant genotype Reference 
SCUPC2R14EG2A SCUPC2R14A ERG11/erg11::PERG11-GFP-caSAT1 
Heilmann et al., 
2010 [89] 
SCUPC2R14EG2B SCUPC2R14B ERG11/erg11::PERG11-GFP-caSAT1 
Heilmann et al., 
2010 [89] 
 
2.5 Growth and maintenance of C. albicans strains 
All strains were stored as frozen stocks with 15% glycerol at -80°C and sub 
cultured on YPD agar plates (10 g yeast extract, 20 g peptone, 20 g dextrose, 15 g agar per 
liter) at 30°C. Strains were routinely grown in YPD liquid medium at 30°C in a shaking 
incubator at 250 rpm.  
2.6 Selection media for C. albicans transformants 
For selection of nourseothricin-resistant transformants, 200 μg/ml nourseothricin 
(Werner Bioagents, Jena, Germany) was added to YPD agar plates. To obtain 
nourseothricin sensitive derivatives in which the SAT1 flipper cassette was excised by 
FLP-mediated recombination, transformants were grown overnight in either YPM medium 
(10 g yeast extract, 20 g peptone, 20 g maltose per liter) without selective pressure to 
induce the MAL2 promoter, or in YCB-YE-BSA medium (23.4 g Yeast Carbon Base, 2 g 
Yeast Extract, 4 g Bovine Serum Albumin, pH 4) to induce the SAP2-1 promoter that 
controls the expression of the caFLP gene in the SAT1 flipper cassette. One hundred to 200 
cells were then spread on YPD plates containing 10 μg/ml nourseothricin and grown for 2 
days at 30°C. Nourseothricin-sensitive clones were identified by their small colony size 
and confirmed by restreaking on YPD plates containing 200 μg/ml nourseothricin. For the 
ΔΔada2 mutants, cells were spread on normal YPD agar plates since they resulted 
hypersensitive to nourseothricin. In this case no difference in size was observed between 
the Nourseothricin-resistant and the nourseothricin-sensitive clones. 
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2.7 Growth and maintenance of E. coli strains 
Recombinant E. coli strains were routinely grown in LB liquid medium (1% 
Peptone, 0.5% Yeast extract, 0.5% NaCl) under the selection pressure (100 μg/ml 
ampicillin). For growth on plates, 1.5% agar [DifcoTM agar granulated, BD] was added to 
the media. The cells were grown at 37°C for 16-18 hours with shaking at 200 rpm and the 
plates were incubated at 37°C until the colonies appeared. While liquid cultures were 
processed to isolate plasmid DNA, the plates with streaked colonies were stored at 4ºC. 
2.8 Small scale plasmid DNA isolation (Miniprep) 
Miniprep was carried out using a commercial kit by Macherey-Nagel 
(Nucleospin® Plasmid) according to manufacturer‟s guideline. After cultivation of liquid 
cultures, cells were harvested by spinning at 11,000 x g for 30 sec. The surnatant was 
carefully removed and the pellet vigorously resuspended in 250 μl Buffer A1. 250 μl of 
Buffer A2 was then added and the mixture gently mixed by inverting the tube 6-8 times. 
The mixture was incubated at room temperature for 5 min until the lysate appeared clear. 
300 μl of Buffer A3 was added to the lysate and the tube gently inverted 6-8 times. The 
lysate was so centrifuged for 5 min at 11,000 x g and the clearified supernatant was loaded 
on the kit columns placed on a collection tube. The column was spinned for 1 min at 
11,000 x g, the flowthrough discarded and the column placed back on the collection tube. 
The column‟s silica membrane was then washed by adding 600 μl Buffer A4, the column 
spinned for 1 min at 11,000 x g and the flowthrough discarded. The silica membrane was 
then dried by spinning the column for further 2 minutes in the same collection tube. The 
plasmid was eluted by transferring the column on a clean 1.5 ml microcentrifuge tube, 
adding 50 μl of double distilled water directly on the membrane, incubating for 1 minute at 
room temperature and spinning down for 1 min at 11,000 x g. 
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2.9 Polymerase Chain Reaction (PCR) 
A high fidelity DNA polymerase either Phusion (Finnzymes) or Elongase 
(Invitrogen) was used for all PCR applications. Usually the PCR reaction volume was 50 
μl, which contained 1-2 ng plasmid DNA or 0.1-0.5 μg genomic DNA as template, 0.2 mM 
of each dNTP, 0.5 μM of each primer, 1 unit of enzyme and polymerase specific buffer. 
The PCR reaction was performed on the “Cyclone 25” Thermocycler (Peqlab) following 
the programme recommended by the enzyme manufacturers. 
The cycling conditions when using Phusion enzyme were the following: 
Initially the DNA was denatured at 98°C for 30 s followed by 30 cycles of 
amplification. 
 Denaturation at 98°C for 10 s 
 Annealing temperature (optimized) 45-55°C for 30 s 
 Extension at 72°C for 30 s /1 kb product 
 Final extension was done at 72°C for 10 minutes in order to fill the 
incomplete extension products. The annealing temperature was adjusted on the basis of the 
Tm of the primers used for amplification. The template amount, number of cycles and 
cycling conditions were varied to maximize the product yield. Successful amplification 
was confirmed by agarose gel electrophoresis and the PCR product was purified using a 
Macherey-Nagel kit (Macherey-Nagel GmbH, Düren, Germany). 
2.10 Plasmid DNA digestion with restriction enzymes 
Plasmid DNA digestions were performed using the appropriate enzyme from New 
England Biolabs (New England Biolabs GmbH, Frankfurt am Main, Germany) with the 
supplied digestion buffers. The amount of enzyme per g of DNA used was according to 
manufacturer‟s instructions. All preparative digestion reactions were generally purified in a 
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50 μl reaction volume, at 37ºC for 6 h, containing 30-35 μl of plasmid DNA (inserts) or 10 
μl of plasmid DNA (vectors). The digest products were then loaded on a 1% agarose gel 
along with 1 kb DNA ladder (Invitrogen). 
2.11 Gel electrophoresis and gel elution of DNA fragments 
Agarose gel electrophoresis of DNA was routinely carried out in 1x TAE (1 liter 
50x TAE stock solution: 242 g Tris base, 57.1 ml glacial acetic acid and 100 ml 0.5 M 
EDTA pH 8.0 in distilled water). After electrophoresis, gels were stained in ethidium 
bromide (10mg/ml in water) and photographed using a gel documentation system (Bio-
Rad). The sizes of the fragments were estimated by measuring the relative mobility of the 
bands in comparison to markers of known molecular size (1 kb DNA ladder, Invitrogen), 
run in a lane alongside. 
To obtain the fragment of interest, digested DNA sample (transformation cassette 
from plasmid preparation, digested PCR products or plasmid inserts) was loaded on the 
agarose gel and run overnight at low voltage (38V) till the band of interest was well 
separated from the vector backbone. The required band was cut out with a scalpel. The 
DNA was eluted from the gel slice using the Macherey-Nagel "PCR cleanup/Gel 
extraction" kit (NucleoSpin Extract II) according to the manufacturer‟s guidelines. 
Concentration of the eluted fragments was checked by "NanoDrop 1000" (Thermo 
Fisher Scientific, Wilmington, MA). 
2.12 Cloning gene of interest in vectors 
2.12.1 Ligation 
The vector used in these studies was pBluescript KS II (Stratagene, Heidelberg, 
Germany). Ligation reactions were set up putting the appropriate volume of each fragment 
in order to have the same amount of molecules for each fragment, in a 20 μl reaction 
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volume containing 1 μl T4 ligase (Invitrogen) and 2 μl of 10x ligase buffer. A vector-only 
control ligation reaction was also set up during each ligation experiment. Ligation 
reactions were carried out over night in a cold water bath (starting temperature 10°C). 
2.12.2 Preparation of E. Coli DH5α competent cells 
E. coli competent cells were prepared using the calcium chloride method. A single 
colony of DH5α was inoculated in 10 ml LB medium and grown at 37°C with shaking at 
200 rpm for 16-18 hours. The overnight grown culture was diluted 1:100 in 50 ml fresh LB 
medium and incubated at 37°C shaker for 3-4 hours (till OD600= 0.7-0.9). The culture was 
then transferred to chilled 50 ml tubes and centrifuged at 3,000 rpm for 10 min at 4°C in a 
chilled rotor. The supernatant was discarded and the cell pellet was resuspended in 40 ml 
of ice cold 50 mM calcium chloride. The cell mix was incubated on ice for 30 minutes and 
centrifuged at 4,000 rpm for 10 minutes at 4°C. The pellet was then resuspended gently in 
4 ml of 50 mM calcium chloride and 86% glycerol was added to a final concentration of 
15% (v/v). Aliquotes of 100 μl competent cells were made in microcentrifuge tubes and 
stored at -80°C for later use. 
2.12.3 Transformation of competent cells 
For each transformation a frozen aliquot of competent cells was thawed on ice. The 
ligation reaction mixture (20 μl) was added to 100 μl competent E. coli cells and incubated 
for 30 minutes on ice. The cells were subjected to heat shock at 42°C for 45 seconds and 
then chilled on ice for 2 minutes. After adding 1 ml LB medium the cells were allowed to 
grow for 1h at 37°C. Finally, the cells were spread on LB selection plate (containing 
ampicillin). Plates were incubated at 37°C until the colonies appeared (~16 hours). 
2.12.4 Screening of recombinants 
Three μl of miniprep plasmid DNA of clones were digested with appropriate 
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restriction enzymes at 37°C in a 20 μl reaction mix for 1-2 h and separated on a 1% 
agarose gel. After staining in ethidium bromide the gel was observed in gel documentation 
system and correct recombinants were selected based on their expected band pattern on 
gel. Sequences of these clones were also verified, in order to avoid selecting recombinants 
with undesired nucleotide substitutions that can arise in PCR. For sequencing of the cloned 
fragments, 1 μl isolated plasmid DNA was mixed with 1 μl primer (20 μM) appropriate for 
the selected cloned fragment to be sequenced, and 5 μl distilled water, and sent to 
Sequence Laboratories Göttingen GmbH (Göttingen, Germany). 
2.13 C. albicans transformation 
C. albicans strains were transformed by electroporation as described by Köhler et 
al., (1997), with minor modifications [91]. A single colony of the strain to be transformed 
was inoculated in 10 ml YPD medium, grown overnight at 30ºC shaker (250 rpm). Cells 
from the pre-culture were diluted 10
-4
 in 50 ml fresh YPD medium and grown at 30°C 
shaker till the culture reached mid log phase (OD600= 1.6-2.2). Cells were collected by 
centrifugation at 4,000 rpm at 4°C for 5 minutes. The cell pellet was then suspended in 8 
ml of sterile distilled water. After addition of 1 ml of 10x TE (100 mM Tris-HCl pH 7.5, 10 
mM EDTA, pH 7.5) and 1 ml of 1M lithium acetate (pH 7.5), the suspension was 
incubated in a rotary shaker for 60 minutes at 30°C. 250 μl of 1 M dithiothreitol (DTT) 
was then added, and the cells were incubated again for 30 min at 30°C with shaking. After 
addition of 40 ml of water the cells were centrifuged (4,000 rpm, 4°C, 5 minutes), cell 
pellet was then washed sequentially in 25 ml of ice-cold water and 5 ml of ice-cold 1 M 
sorbitol. The supernatant was discarded and the washed cell pellet was resuspended in the 
residual liquid and kept on ice. 
Five μl of the linear DNA fragment were mixed with 40 μl of electrocompetent 
cells in a 0.2 cm cuvette (PeqLab, Erlangen, Germany). For control, 5 μl of sterile distilled 
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water was used instead of DNA. Electroporation was carried out at 1.8 kV using an 
electroporation apparatus (Equibio, Kent, UK). After electroporation, the cells were 
transferred to 2 ml microcentrifuge tubes using 1 ml of YPD medium. The electroporated 
cells, after resuspension in 1 ml YPD medium, were divided into two aliquots so that two 
independent first round transformants could be obtained. The volume of each aliquot was 
adjusted to 1 ml by adding 500 μl YPD and the samples were then incubated for 4-6 h at 
30°C. Following incubation, 100 μl from the sample was spread on YPD plates containing 
200 μg/ml of nourseothricin. The plates were incubated at 30°C until colonies appeared. 
Individual colonies were streaked on respective selection media plates for further analysis. 
2.14 Genomic DNA isolation from C. albicans 
A single colony of the strain of which genomic DNA has to be isolated was 
inoculated in 10 ml YPD medium and grown overnight at 30ºC in a shaker (250 rpm). 
Cells were then pelletted by centrifugation at 3,000 rpm for 5 minutes, washed twice with 
1 ml distilled water and then broken by vortexing for 5 minutes at maximum speed 
together with 200 μl Breaking Buffer (2% v/v TritonX 100, 1% v/v SDS, 100 mM NaCl, 
10 mM Tris-Cl pH 7.5, 1 mM EDTA pH 7.5), 0.3 g Glass Beads (0.5 mm Φ) and 200 μl 
PCI (phenol/chloroform/IAA, 25:24:1). After addition of 200 μl of TE buffer (10 mM Tris-
Cl pH 7.5, 1 mM EDTA pH 7.5) samples were centrifuged for 5 minutes at 13,000 rpm. 
The surnatant was then transferred in a new microcentrifuge tube and precipitated first 
with 1 ml 96% ethanol and then with 600 μl of 70% ethanol. The pellet was left to dry 
completely and then resuspended in 100 μl TE buffer with 0.1 mg/ml RNase. 
2.15 Southern hybridization 
Ten μg of genomic DNA from C. albicans transformants were digested overnight 
with appropriate restriction enzymes in a 30 μl reaction volume at 37°C. Digested samples, 
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along with 1 kb DNA ladder (Invitrogen) as marker, were loaded on a 1% agarose gel. The 
gel was run overnight at 36-40 V in 1x TAE buffer. After electrophoresis the gel was 
stained with ethidium bromide, and photographed. 
For DNA transfer, a nylon membrane (15 cm x 14 cm, Schleicher & Schuell, 
Dassel, Germany) was pre-wet for few seconds in distilled water and equilibrated in 20x 
SSC (3 M NaCl, 0.3 M tri-sodium citrate dihydrate) for 5 minutes. The gel was rinsed with 
distilled water and aligned on top of the membrane in vacuum blot apparatus (Phamacia 
Biotech). In a sequential order, the gel was treated with different solutions (15 min each) 
under vacuum, Solution A (0.25 N HCl) for depurination of the DNA, Solution B (1.5 M 
NaCl, 0.5 N NaOH) for denaturing DNA and then with Solution C (1.5 M NaCl, 0.5 M 
Tris-Cl pH 7.5) for neutralization. Transfer was done with 20x SSC for 90 minutes. After 
the transfer was complete, the membrane was first soaked in 0.4N NaOH for 1 minute to 
denature the DNA and then treated with 0.2M Tris-Cl (pH 7.5) for 1 minute for 
neutralization. The wet membrane was placed on Whatmann filter paper and DNA was 
fixed to membrane by UV-cross linking using Stratalinker (Stratagene). 
Hybridization was performed with the „ECL labelling and detection kit‟ (GE 
Healthcare, Braunschweig, Germany) according to manufacturer‟s instructions. The 
membrane was prewet in 2x SSC for 1 minute and then placed in a hybridization bottle. 
For prehybridization, the membrane was incubated with 15 ml ECL hybridization buffer 
for 1 h at 42°C in a hybridization oven. The probe was prepared according to 
manufacturer‟s instruction using 100 ng DNA of interest (gel eluted) and 2 ng 1 kb DNA 
ladder (Invitrogen) and then was added to the prehybridization buffer. Hybridization was 
carried out at 42°C for 16-18 hours. After hybridization, the membrane was washed at 
42°C three times with Wash Buffer I (6 M Urea, 0.4% SDS, 0.5x SSC) for 10 minutes and 
twice in 2x SSC at RT for 5 minutes. For signal detection, the washed membrane was 
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incubated in a mixture of detection solution 1 and 2 (1:1) for 1 min, then wrapped securely 
in saran wrap, and finally exposed to Amersham hyperfilm ECL in a film cassette for 1 h. 
For rehybridizing with a second probe the blot was washed in 2x SSC for 10 min and then 
steps for hybridization were followed as described above. 
2.16 Analysis of MDR1 gene expression by quantitative real-time 
reverse transcription PCR 
2.16.1 RNA isolation from C. albicans 
All solutions used for RNA isolation were made either in DEPC treated water or 
treated with DEPC after preparation and RNase-free plastic ware was used in all 
procedures of RNA handling. For DEPC treatment 0.1% DEPC (v/v) was added and the 
solutions were incubated at 37°C overnight and autoclaved. 
Total RNA was isolated from early log-phase C. albicans cultures in liquid YPD 
medium by the hot phenol method combined with a purification step with RNeasy kit 
(Qiagen, Hilden, Germany). A single colony of the Candida strain was inoculated in 10 ml 
YPD medium and grown overnight at 30ºC shaker (250 rpm). Cells from the preculture 
were diluted 10
-2
 in 50 ml fresh YPD medium and grown at 30°C shaker for 4 more hours. 
Where needed, doxycycline was added at a final concentration of 20 μg/ml. After 4 h of 
incubation, cultures were transferred to 50 ml centrifuge tubes and centrifuged for 3 
minutes at 2500 x g at 4°C. Surnatant was discarded and the pellet resuspended in 1 ml ice-
cold water and transferred in a 2 ml microcentrifuge tube. After centrifuging the samples 
for 10 seconds at 4°C, the pellet was resuspended in 400 μl TES solution (10 mM Tris-Cl 
pH 7.5; 10 mM EDTA pH 7.5; 0.5% SDS) and 400 μl of Acid Phenol (Aqua Roti Phenol, 
Roth, Germany) was added to the samples. The tubes were vigorously vortexed and 
incubated for 1 h at 65°C with occasional, brief vortexing. The samples were then chilled 
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on ice for 5 minutes and centrifuged at 11,000 x g for 5 minutes at 4°C. At this point, the 
aqueous top phase was transferred to a new 1.5 ml tube and mixed well with 1 vol buffer 
RLT (Qiagen kit) and 1 vol pure Ethanol. The mixture could so be transferred on the 
RNeasy mini column placed on a 2 ml collection tube. Columns were then centrifuged for 
15 seconds at max speed, flowthrough discarded and 700 μl of buffer RW1 was added. 
Again columns were briefly centrifuged, flowthrough discarded and two steps with 500 μl 
of buffer RPE were performed. Columns were then placed on a new collection tube and 
spinned for 1 minute to be sure to get rid of all buffer. Columns were then placed on a 1.5 
ml fresh microcentrifuge tube, 50 μl of RNase-free water was added directly to the 
columns membrane, and the total RNA was so eluted centrifuging the columns for 1 
minute. Half the volume was immediately stored at -80°C and half was kept on ice for 
performing DNAse treatment 
2.16.2 DNase treatment 
Contaminating DNA was removed by treatment with the Ambion Turbo DNA-free 
kit (Applied Biosystems, Darmstadt, Germany). The RNA was incubated for 20 minutes at 
37°C together with 0.1 vol 10X TURBO DNase buffer (3 μl) and 1 μl TURBO DNase. 
DNase was then inactivated by adding 0.1 vol resuspended DNase Inactivation Reagent (3 
μl) and by mixing well. After incubating for 2 minutes at room temperature, samples were 
centrifuged at max speed for 2 minutes to spin down the inactivating reagent so that RNA 
could be collected from the upper phase and transferred to a clean tube. A second 
purification step was performed on the DNase treated RNA with the same RNeasy kit 
(Qiagen) as above, following the manufacturer‟s instructions. 
2.16.3 RNA quantity and quality controls 
The absence of genomic DNA was controlled by PCR, concentration was checked 
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with a NanoDrop 1000 analyser and the absence of RNA degradation was checked by 
letting the RNA run on a 1% agarose gel (TAE buffer) for 1 h at 70 V. Good quality RNA 
gave 3 bands, one for rRNA 18S, one for rRNA 28S and one for the complex of the two 
RNAs. 
2.16.4 Conversion of RNA into cDNA 
RNA was converted into cDNA with the SuperScript® III Reverse Transcriptase kit 
(Invitrogen, Karlsrhue, Germany) following the manufacturer‟s instructions. Generation of 
cDNA was checked by PCR using primers which bind outside an intron. Amplification of 
cDNA gave a smaller PCR product while amplification of genomic control DNA gave a 
bigger band. 
2.16.5 Real Time PCR 
qPCR was performed with the iQ
TM
 SYBR® Green Supermix (Bio-Rad) and the 
primer pairs MDR5RT and MDR6RT for MDR1, ACT1RT and ACT2RT for ACT1, which 
served as the reference, using the following conditions: an initial denaturation for 3 min at 
95°C, 40 cycles of 30 sec 95°C, 40 sec 50°C, 10 sec 72°C, one cycle of 30 sec 95°C, 30 
sec 57°C. Melt curves were generated and Ct values calculated by the Real Time program, 
Bio-Rad iQ5 V2.0 optical systems software. Ct values obtained by the software were then 
used to calculate the relative MDR1 mRNA levels adjusted to the ACT1 mRNA levels and 
using MDR1 expression in the wild-type strain SC5314 as a reference (set to 1). Two 
independent RNA extractions, each with two technical replicates, were used to calculate 
mean and standard deviation of the final relative expression values.  
2.17 Analysis of MDR1 promoter activity by FACS analysis in the 
conditional mcm1 mutants 
YPD overnight cultures of GFP reporter and parental control strains were each 
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diluted 10
-2
 in six Erlenmeyer flasks containing 50 ml YPD medium (three without and 
three with 20 μg/ml doxycycline). After 3 h of growth at 30°C, 50 μg/ml benomyl or 
0.005% H2O2 was added to two of the cultures (in both cases with and without 
doxycycline) to induce MDR1 expression; the other two cultures were left untreated. 
Following 60 min of further incubation the mean fluorescence of the cells was determined 
by flow cytometry. Fluorescence-activated cell sorter (FACS) analysis was performed with 
a FACSCalibur cytometry system equipped with an argon laser emitting at 488 nm (Becton 
Dickinson, Heidelberg, Germany). Fluorescence was measured on the FL1 channel 
equipped with a 530-nm band-pass filter. Twenty thousand cells were analyzed per sample. 
Fluorescence data were collected by using logarithmic amplifiers. The mean fluorescence 
values were determined with CellQuest Pro (Becton Dickinson) software. 
2.18 Analysis of MDR1, CDR2 and ERG11 promoter activity by FACS 
analysis in the ΔΔada2 mutants 
Procedures for ΔΔada2 mutants were the same as for the mcm1 mutants, with the 
difference that the volume in which the strains were grown was 3 ml instead of 50 ml, the 
presence of doxycycline was not needed and the other inducing chemicals, fluphenazine 
for CDR2 induction and ketoconazole for ERG11 induction, were used at a concentration 
of 10 µg/ml and 0.5 µg/ml respectively. 
2.19 Confirmation of doxycycline-induced MCM1 repression by 
Western immunoblotting 
Strains can43MPG2A/B were grown as described above for determining GFP 
expression. Whole cell protein extracts were prepared from two cultures grown for 3 h in 
the presence or absence of doxycycline and from the remaining cultures after further 60 
min incubation in the presence of benomyl or H2O2 (with and without doxycycline). Cells 
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were collected by centrifugation, washed twice in water, and broken by vortexing for 10 
min at 4°C with 300 μl 0.5-mm glass beads in 300 μl breaking buffer (100mM Tris-Cl [pH 
7.5], 200 mM NaCl, 20% glycerol, 5 mM EDTA, 4% of a Complete EDTA-free Protease 
Inhibitor Cocktail stock solution [Roche Diagnostics GmbH, Mannheim, Germany], 0.1% 
β-mercaptoethanol). Samples were centrifuged at 13,000 rpm for 5 min at 4°C, the 
supernatant collected, and the protein concentration quantified with a NanoDrop 1000 
(Thermo Fisher Scientific, Wilmington, MA). Extracts were heated at 65°C for 10 min and 
400 μg total protein of each sample was separated on an SDS-12% polyacrylamide gel. 
Proteins were transferred onto nitrocellulose membrane with a Trans-Blot SD Semi-Dry 
transfer apparatus (Bio-Rad, Munich, Germany). For detection of Mcm1-Myc, a 
monoclonal anti-c-Myc antibody (purified mouse immunoglobulin, clone 9E10, Sigma-
Aldrich Chemie GmbH, product number M4439) was used as primary antibody at a 
dilution of 1:6000, and goat anti-mouse IgG (Fab-specific) peroxidase conjugate (Sigma 
A9917) was used as a secondary antibody at a dilution of 1:6000. Blots were developed 
using a chemiluminescence detection system (GE Healthcare UK Limited, Chalfont, UK) 
under conditions recommended by the manufacturer. 
2.20 MIC test 
Minimal inhibitory concentration of the C. albicans strains was determined by a 
microdilution assay in 96 well microtiter-plates. Strains were tested for fluconazole and 
cerulenin susceptibility. Stock solutions of the drugs were prepared, fluconazole was 
dissolved in water while cerulenin was dissolved DMSO, and both stock solutions were 
prepared at a concentration of 5 mg/ml and stored at 4°C. The medium used for the test 
was a minimal medium (SD) which was prepared as follows: YNB with the addition of 
ammonium sulfate (6.7 g) was solved in 800 ml water, pH was brought to 5.8 by adding 
NaOH, after autoclaving glucose was added (final concentration of 2%, 100 ml of a 20% 
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stock solution) and 100 ml of a 10X stock of CSM mix were added. CSM 10X mix was 
prepared by dissolving 7.9 g of CSM powder in 1 l water and sterile filtrating it. The test 
was performed by resuspending 1 fresh colony (2 days old) in 1 ml 0.9% NaCl, 4 μl of the 
cell suspension were then resuspended in 2 ml SD medium and 100 μl of the obtained 
suspension were then mixed on the microtiter-plate together with different dilutions of the 
drug to be tested. Starting concentrations of the drugs were 50 μg/ml and 1:2 serial 
dilutions were performed, diluting in SD medium, until concentration 0.02 μg/ml. The 
plates were incubated at 37°C for 48 h and MIC readings were then performed considering 
the MIC value as the first concentration where there was no visible growth.  
2.21 Spot assays 
Spot assays were performed on YPD agar plates or N10 agar plates (YPD + 10 
μg/ml Nourseothricin). Overnight cultures in YPD liquid medium (10 ml) were diluted 10-2 
and optical density was measured at a 600 nm wavelength. Starting cell concentration was 
adjusted to OD=10 and serial 1:10 dilutions were performed until OD=10
-4
. Five μl of each 
cell concentration were then plated on the agar plates, the drop let to dry and the plates 
incubated at 30°C. After 48 h pictures were taken. 
  
3 RESULTS 
3.1 Role of Mcm1 in the regulation of MDR1 
3.1.1 Introduction of a PMDR1-GFP reporter fusion 
To monitor the activation of the MDR1 promoter in response to inducing chemicals 
in the presence and absence of Mcm1, a PMDR1-GFP reporter fusion was introduced into 
the conditional mcm1 mutant MRcan42, which contains a single, Myc-tagged MCM1 allele 
under the control of a tetracycline-repressible promoter. In addition, the reporter fusion was 
introduced into the control strain MRcan43, which contains both a tetracycline-repressible 
MCM1 copy and a Myc-tagged MCM1 allele with its own promoter. To this aim, a 
KpnI/SacII fragment from plasmid pMPG2S (Fig. 2; Table 2) was used to transform the 
parental strains. This led to the replacement of one copy of the ACT1 gene with the so 
formed cassette. 
 
Fig. 2. Structure of the cassette from plasmid pMPG2S. 
ACT1 coding region is replaced by the MDR1 promoter (PMDR1) fused with the GFP 
protein (GFP***). The ACT1 transcription termination sequence (ACT1t) was used for 
a correct termination of the GFP transcription. The cassette contains a selective 
resistance marker, caSAT1, which confers resistance to nourseothricin. 
Two independent transformants of each parental strain were used for further 
analysis, named can42MPG2A/B and can43MPG2A/B respectively. SC5314 background 
3’ACT1 PMDR1 GFP*** ACT1t caSAT1 PACT1
KpnI SacII
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mutants where already present in the laboratory‟s collection, named SCMPG2A/B (Table 
3). 
3.1.2 Confirmation of Mcm1 depletion 
To confirm that Mcm1 could be efficiently depleted by addition of doxycycline to 
the conditional mutants carrying the reporter fusion and that the presence of the MDR1 
inducers, benomyl and H2O2, did not affect doxycycline-mediated repression, Western Blot 
analysis was performed. As shown in Fig. 3, Mcm1 was not detectably expressed after 3 h 
of growth in the presence of doxycycline, and the addition of benomyl or H2O2 did not 
alleviate this repression. 
 
Fig. 3. Depletion of Mcm1 from reporter strains by treatment with doxycycline. 
Strains ca42MPG2A/B were grown in the absence (-) or presence (+) of doxycycline 
(Doxy) and treated with benomyl (Ben) or H2O2 as described in Materials and 
Methods. Whole cell protein extracts were prepared and analyzed by western 
immunoblotting with anti-Myc antibody. The position of Myc-tagged Mcm1 is 
indicated; an unspecific cross-reacting band served as loading control. The figure 
shows the results for strain cand42MPG2A; the same results were obtained with 
can42MPG2B. 
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3.1.3 Determination of MDR1 promoter activity by FACS analysis 
MDR1 promoter activity was determined by quantifying the fluorescence of the 
reporter strains (Fig. 4). As previously reported [46], expression of MDR1 was not 
detectable in the wild-type strain SC5314 in YPD medium, but it could be induced by 
H2O2 treatment and, even more efficiently, by benomyl.  
 
Fig. 4. Activation of the MDR1 promoter. 
Activation of the MDR1 promoter by H2O2 and benomyl in the wild-type strain 
SC5314, the conditional mcm1 mutant MRcan42, and the control strain MRcan42. 
Parental strains and transformants carrying a PMDR1-GFP reporter fusion were grown 
in the absence (-) or presence (+) of doxycycline (Dox) and treated with H2O2 or 
benomyl (Ben) as described in Materials and Methods. The mean fluorescence of the 
cells was determined by flow cytometry. The results obtained with two independently 
generated reporter strains (SCMPG2A/B, can42MPG2A/B, can43MPG2A/B) are 
shown in each case. The background fluorescence of the parental strains, which do not 
contain the GFP gene, is indicated by the black part in each column. 
The presence of doxycycline did not affect the activity of the MDR1 promoter 
under non-inducing or inducing conditions in the wild-type background. H2O2 also induced 
the MDR1 promoter in the conditional mutant MRcan42, although less efficiently than in 
strain SC5314, and this induction was also observed after depletion of Mcm1. In contrast, 
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Mcm1 depletion resulted in a reduced induction of the MDR1 promoter by benomyl, as the 
fluorescence of the conditional mutants was decreased in the presence of doxycycline. 
Doxycycline had a little effect on benomyl-induced MDR1 expression in the control strain 
MRcan43. These results demonstrate that Mcm1 is dispensable for the induction of MDR1 
expression by H2O2, but it is required for full MDR1 induction by benomyl. 
3.1.4 Introduction of hyperactive transcription factors for constitutive MDR1 
overexpression 
The induction of the MDR1 promoter by H2O2 requires the bZIP transcription factor 
Cap1, which is activated by oxidative stress. Cap1 also contributes to, but is not essential 
for benomyl-induced MDR1 expression. In contrast, the zinc cluster transcription factor 
Mrr1 is indispensable for MDR1 expression in the presence of either of these inducers. 
As Mcm1 was necessary for full benomyl-induced, but not for H2O2-induced 
MDR1 expression, it was investigated whether Mcm1 was required for the constitutive 
MDR1 overexpression caused by hyperactive forms of Mrr1 and Cap1. To this aim, the 
P683S gain-of-function mutation was introduced into both resident MRR1 alleles of the 
conditional mcm1 mutant MRcan42 and the control strain MRcan43. The transformation 
cassette used for this purpose is a SacI/ApaI fragment form plasmid pMRR1R3 (Fig. 5). 
  
 
43 Results, 
 
Fig. 5. Structure of the cassette from plasmid pMRR1R3. 
MRR1 coding region is replaced by an MRR1 allele containing a P683S substitution. 
The cassette contains the FLP recombinase gene (caFLP) under the control of the 
MAL2 promoter (PMAL2) and a selective resistance marker (caSAT1) which confers 
resistance to nourseothricin. ACT1 transcription termination sequences (ACT1t) served 
for terminating both MRR1 and caFLP transcription. FLP recombination target 
sequences (FRT) are not drawn to scale. 
In addition, both wild-type CAP1 alleles of these strains were replaced by the C-
terminally truncated, hyperactive CAP1
ΔC333
 allele with a SacI/ApaI fragment from 
plasmid pCAP1R1 (Fig. 6). 
 
Fig. 6. Structure of the cassette from plasmid pCAP1R1. 
CAP1 coding region is replaced by a truncated CAP1 allele. The cassette contains the 
FLP recombinase gene (caFLP) under the control of the MAL2 promoter (PMAL2) and a 
selective resistance marker (caSAT1) which confers resistance to nourseothricin. ACT1 
transcription termination sequences (ACT1t) served for terminating both CAP1 and 
caFLP transcription. FLP recombination target sequences (FRT) are not drawn to 
scale. 
Homozygous strains were generated since the activating mutations in MRR1 and 
CAP1 have a stronger effect on MDR1 expression when they are present in both alleles 
(Schubert et al., submitted). Two independent series of mutants (A and B) were constructed 
in each case and used for further analysis. 
PMAL2MRR1
P683S ACT1t caSAT1 caFLP
SacIApaI
ACT1t 3’MRR1
FRT FRT
PMAL2CAP1ΔC333 ACT1t caSAT1 caFLP
SacI ApaI
ACT1t
FRT FRT
3’CAP1
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3.1.5 Quantitative Real-Time PCR for determining MDR1 expression 
As the MDR1 promoter is constitutively activated in strains expressing hyperactive 
Mrr1 or Cap1, GFP was not useful as a reporter to measure the dependence of MDR1 
expression on Mcm1, because considerable amounts of the relatively stable GFP protein 
would remain in the cells after shutting off MCM1 expression by the addition of 
doxycycline. Therefore, MDR1 mRNA levels were measured in the presence and absence 
of doxycycline by quantitative RT-PCR. As shown in Fig. 7, MDR1 was constitutively 
expressed at high levels in strains carrying the CAP1
ΔC333
 allele (between 250- and 400-
fold higher than in the control strain SC5314) and Mcm1 depletion in the conditional 
mcm1 mutants by doxycycline did not significantly reduce MDR1 mRNA levels. MDR1 
expression was even higher in strains containing the hyperactive MRR1
P683S
 allele 
(between 1200- and 2200-fold higher than in the control strain SC5314). Mcm1 depletion 
by doxycycline resulted in a drastic reduction of MDR1 mRNA levels in the conditional 
mutants (between 20- and 30-fold). A moderate reduction of MDR1 mRNA levels (2.5-
fold) was also observed in the control strains containing the hyperactive MRR1
P683S
 allele 
after addition of doxycycline, but not in the control strains carrying the CAP1
ΔC333
 allele. 
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Fig. 7. Real-time analysis for MDR1 expression. 
Effect of Mcm1 depletion on MDR1 overexpression mediated by hyperactive forms of 
Cap1 and Mrr1. The wild-type strain SC5314, the conditional mcm1 mutant 
MRcan42, control strain MRcan43, and independent derivatives (A and B) of 
MRcan42 and MRcan43 that were rendered homozygous for the CAP1
ΔC333
 or the 
MRR1
P683S
 alleles were grown for 4 h in the absence (blue bars) or presence (red bars) 
of doxycycline as described in Materials and Methods. MDR1 mRNA levels were 
determined by real time RT-PCR and are presented as relative expression levels 
compared to those of the reference strain SC5314 in the absence of doxycycline, 
which were set to 1. The graph shows the means and standard deviations of two 
independent experiments with duplicate measurements performed with each strain. 
*MDR1 expression levels in SC5314 and the parental strains MRcan42 and MRcan43 
were too low to be visible. 
These results indicate that a hyperactive Cap1 can mediate MDR1 overexpression 
independently of Mcm1, whereas a hyperactive Mrr1 requires Mcm1 to promote MDR1 
expression. 
3.2 Role of Ada2 in the regulation of MDR1, CDR2 and ERG11 
In order to investigate the role of Ada2 in the regulation of MDR1, CDR2 and 
ERG11, genes known to be involved in drug resistance mechanisms, the gene was knocked 
out from the parental SC5314 C. albicans reference strain. The aim was to evaluate how C. 
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albicans behaves in different conditions in the absence of Ada2 and in the presence of 
hyperactive alleles of different transcription factors known to be involved in the regulation 
of the above mentioned genes. These include: CAP1
ΔC333
, CAP1 truncated hyperactive 
allele, and MRR1
P683S
, MRR1 hyperactive allele, which regulate MDR1, TAC1
G980E
, 
hyperactive TAC1 allele which regulates CDR2, or UPC2
G648D
, hyperactive UPC2 allele 
which regulates ERG11. 
3.2.1 Knock out of ADA2 gene 
The first ADA2 destruction cassette was produced as follows: one fragment of the 
downstream region of the ADA2 gene was amplified with primers ADA2-3 and ADA2-4 
(Table 1) from genomic SC5134 DNA. The PCR product was digested with XhoI/ApaI and 
cloned in the XhoI/ApaI digested pCAP1M4 plasmid. The produced plasmid was named 
pADA2M1 (Fig. 8) and contained only the downstream region of the ADA2 gene.  
 
Fig. 8. Structure of the cassette from plasmid pADA2M1. 
Downstream region of gene ADA2 (3’ADA2) was cloned in plasmid pCAP1M4. The 
cassette contains the FLP recombinase gene (caFLP) under the control of the SAP2-1 
promoter (PSAP2-1) and a selective resistance marker (caSAT1) which confers resistance 
to nourseothricin. ACT1 transcription termination sequences (ACT1t) served for 
terminating caFLP transcription. FLP recombination target sequences (FRT) are not 
drawn to scale. 
To introduce the upstream region of ADA2 gene a PCR product was amplified with 
primers ADA2-5 and ADA2-6 (Table 1) from genomic SC5314 DNA. The PCR product 
was digested wit SacI/SacII and cloned in the SacI/SacII digested pADA2M1 to produce 
plasmid pADA2M2 (Fig. 9). Differences between pADA2M2 and the upstream sequence 
5’CAP1 PSAP2-1caSAT1 caFLP
SacI ApaI
ACT1t
FR
T
FRT
3’ADA2
 
47 Results, 
of orf19.2331 are: G-498T, T-487Δ, A-458T, T-159Δ, T-158Δ, A-69Δ. 
 
Fig. 9. Structure of the cassette from plasmid pADA2M2. 
Upstream region of gene ADA2 (5’ADA2) was cloned in plasmid pADA2M1. The 
cassette contains the FLP recombinase gene (caFLP) under the control of the SAP2-1 
promoter (PSAP2-1) and a selective resistance marker (caSAT1) which confers resistance 
to nourseothricin. ACT1 transcription termination sequences (ACT1t) served for 
terminating caFLP transcription. FLP recombination target sequences (FRT) are not 
drawn to scale. 
A SacI/ApaI digested fragment of pADA2M2 was used to transform strain SC5314 
in order to knock out one allele of the ADA2 gene, generating strains SCADA2M1A/B. 
After recycling the nourseothricin resistance marker and generating strains 
SCADA2M2A/B, several attempts have been made to knock out the second allele with the 
same cassette from plasmid pADA2M2 without success. A new plasmid containing 
flanking regions internal to the previous ones was then constructed. Therefore, the 
resulting pADA2M3 was as follows: the N-terminal region of the ADA2 gene was 
amplified with primers ADA2-7 and ADA2-8 (Table 1) from genomic SC5314 DNA. The 
C-terminal region of the ADA2 gene was amplified with primers ADA2-9 and ADA2-10 
from genomic SC5314 DNA. PCR products were digested with SacI/SacII and XhoI/ApaI 
respectively and cloned, together with the [SacII/XhoI] SAT1-Flipper-Fragment from 
pADA2M2, in the SacI/ApaI digested pADA2M2, to generate pADA2M3 (Fig. 10). 
PSAP2-1caSAT1 caFLP
SacI ApaI
ACT1t
FR
T
FRT
3’ADA25’ADA2
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Fig. 10. Structure of the cassette from plasmid pADA2M3. 
New upstream and downstream regions of gene ADA2 (5’ADA2, 3’ADA2) were 
cloned in plasmid pADA2M2. The cassette contains the FLP recombinase gene 
(caFLP) under the control of the SAP2-1 promoter (PSAP2-1) and a selective resistance 
marker (caSAT1) which confers resistance to nourseothricin. ACT1 transcription 
termination sequences (ACT1t) served for terminating caFLP transcription. FLP 
recombination target sequences (FRT) are not drawn to scale. 
A SacI/ApaI fragment from pADA2M3 was used to transform the heterozygous 
Δada2 mutants SCADA2M2A/B. The transformation led to the selection of clones which 
had a correctly integrated deletion cassette, but the nourseothricin resistance SAT1 marker 
could apparently not be excised. Since Ada2 could be somehow required for the induction 
of the SAP2 promoter, which should have induced the expression of the FLP-recombinase 
responsible for the excision of the whole cassette from the genome, another knock out 
cassette was constructed. In the new construct, the FLP-recombinase was under the control 
of the MAL2 promoter, which is induced by the presence of maltose in the growth medium. 
For this purpose, a [SacII/XhoI]-Fragment with the SAT1-flipper and the MAL2 promoter 
from plasmid pMRR1R3 was cloned in the SacII/XhoI digested pADA2M3 to form 
pADA2M4 (Fig. 11). 
PSAP2-1caSAT1 caFLP
SacI ApaI
ACT1t
FR
T
FRT
3’ADA25’ADA2
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Fig. 11. Structure of the cassette from plasmid pADA2M4. 
ADA2 knock-out cassette contains upstream and downstream regions of gene ADA2 
(5’ADA2, 3’ADA2), the FLP recombinase gene (caFLP) under the control of the 
MAL2 promoter (PMAL2) and a selective resistance marker (caSAT1) which confers 
resistance to nourseothricin. ACT1 transcription termination sequences (ACT1t) served 
for terminating caFLP transcription. FLP recombination target sequences (FRT) are 
not drawn to scale. 
The new transformation cassette from plasmid pADA2M4 was used to transform 
strains SCADA2M2A/B; clones were isolated but, once again, no derivatives in which the 
SAT1 flipper cassette had been excised were obtained on plates containing 10 μg/ml 
nourseothricin. It was speculated that the double knock out ΔΔada2 mutants were too 
sensitive towards nourseothricin and that could not grow on N10 (YPD + 10 μg/ml 
nourseothricin) plates, where normally the clones that had retained the SAT1 resistance 
marker could be distinguished from the clones that had lost it by the size of the colony. So 
the strains which had been induced to excise the cassette by the presence of maltose in the 
medium were plated on normal YPD medium and then screened for the correct excision. 
Finally the double knock out mutants with the excised SAT1 resistance marker were 
obtained and the newly cloned mutants were named SCADA2M3A/B and 
SCADA2M4A/B, with and without the resistance marker respectively. 
3.2.2 Complementation of ADA2 gene in ΔΔada2 mutants 
In order to demonstrate that the growth defect in the ΔΔada2 mutant was indeed 
due to the absence of Ada2, one copy of the gene was reintegrated in both mutants. The 
3’ADA25’ADA2 PMAL2caSAT1 caFLP
SacI ApaI
ACT1t
FRT FRT
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complementation cassette was constructed as follows: the ADA2 gene including upstream 
and downstream regions was amplified from genomic SC5314 DNA with primers ADA2-
11 and ADA2-12. The PCR product was digested with SacI/XhoI and with XhoI/SacII and 
both fragments were cloned in the SacI/SacII digested pADA2M2 to produce pADA2K1 
(Fig. 12).  
 
Fig. 12. Structure of the cassette from plasmid pADA2K1. 
ADA2 complementation cassette contains ADA2 complete coding region and the 
downstream region of gene ADA2 (3’ADA2), the FLP recombinase gene (caFLP) 
under the control of the SAP2-1 promoter (PSAP2-1) and a selective resistance marker 
(caSAT1) which confers resistance to nourseothricin. ACT1 transcription termination 
sequences (ACT1t) served for terminating caFLP transcription. FLP recombination 
target sequences (FRT) are not drawn to scale. 
The plasmid was digested with ApaI and the complementation cassette was 
transformed in the ΔΔada2 mutants SCADA2M4A/B. The resistance marker was then 
excised by induction of the FLP-recombinase in the presence of BSA. The newly 
generated complementation strains were named SCADA2MK1A/B and 
SCADA2MK2A/B, with and without the selection marker respectively.  
3.2.3 Introduction of hyperactive alleles in the ΔΔada2 mutants 
Double knock out ΔΔada2 mutants (SCADA2M4A/B) were transformed with 
different cassettes to introduce hyperactive alleles of CAP1, MRR1, TAC1 and UPC2 
transcription factors. 
PSAP2-1caSAT1 caFLP
ApaI ApaI
ACT1t
FRT FRT
3’ADA2
ADA2
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A SacI/ApaI fragment from plasmid pCAP1R1 (Fig. 6) was transformed into the 
ΔΔada2 mutants to create strains SCΔada2CAP1R11A/B. The selection marker was 
recycled to create strains SCΔada2CAP1R12A/B and a second round of transformation 
and recycling generated strains SCΔada2CAP1R13A/B and SCΔada2CAP1R14A/B. In 
these strains both original CAP1 alleles were replaced with two hyperactive truncated ones. 
Analogously, a SacI/ApaI fragment from plasmid pMRR1R3 (Fig. 5) was used to 
transform ΔΔada2 mutants to generate, in two rounds of transformation and cassette 
recycling, strains SCΔada2MRR1R34A/B containing MRR1 hyperactive allele. 
A SacI/ApaI fragment from plasmid pTAC1R3 (Fig. 13) was used to introduce the 
TAC1 hyperactive alleles producing strains SCΔada2TAC1R34A/B. 
 
Fig. 13. Structure of the cassette from plasmid pTAC1R3. 
TAC1 coding region is replaced by a TAC1 allele containing a G980E substitution. 
The cassette contains the FLP recombinase gene (caFLP) under the control of the 
MAL2 promoter (PMAL2) and a selective resistance marker (caSAT1) which confers 
resistance to nourseothricin. ACT1 transcription termination sequences (ACT1t) served 
for terminating both TAC1 and caFLP transcription. FLP recombination target 
sequences (FRT) are not drawn to scale. 
Finally, a SacI/ApaI fragment from plasmid pUPC2R1 (Fig. 14) was used to create 
strains SCΔada2UPC2R14A/B containing UPC2 mutated alleles. 
3’TAC13’TAC1G980E PMAL2caSAT1 caFLP
SacI ApaI
ACT1t
FRT FRT
ACT1t
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Fig. 14. Structure of the cassette from plasmid pUPC2R1. 
UPC2 coding region is replaced by a UPC2 hyperactive allele (UPC
G648D
). The 
cassette contains the FLP recombinase gene (caFLP) under the control of the MAL2 
promoter (PMAL2) and a selective resistance marker (caSAT1) which confers resistance 
to nourseothricin. ACT1 transcription termination sequences (ACT1t) served for 
terminating both TAC1 and caFLP transcription. FLP recombination target sequences 
(FRT) are not drawn to scale. 
3.2.4 Introduction of GFP tagged promoter fusions 
In order to monitor the activity of the hyperactive alleles of the four transcription 
factors Cap1, Mrr1, Tac1 and Upc2, a GFP-promoter fusion specific for each one of them 
was introduced in the previously created mutants. 
While the plasmids containing GFP-tagged promoter fusions for genes MDR1 and 
ERG11, targets of Cap1, Mrr1 and Upc2, were already present in the plasmid collection of 
Prof. Morschhäuser‟s group, the plasmid containing the GFP-tagged promoter fusion for 
gene CDR2, target of Tac1, was created in this study. The upstream region of the CDR2 
gene was amplified with primers CDR2-5 and CDR2-6 using genomic SC5314 DNA as 
template. The PCR product was digested with KpnI/SalI and cloned together with a 
[SalI/ClaI][GFP
***
-ACT1t-caSAT1]-fragment from pERG11G2 in the KpnI/ClaI digested 
pCDR2G2. The newly cloned plasmid was named pCDR2G3 (Fig. 15). 
3’UPC2UPC2G648D PMAL2caSAT1 caFLP
SacI ApaI
ACT1t
FRT FRT
ACT1t
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Fig. 15. Structure of the cassette from plasmid pCDR2G3. 
CDR2 promoter (PCDR2) is fused with the GFP protein (GFP***). The ACT1 
transcription termination sequence (ACT1t) was used for a correct termination of the 
GFP transcription. The cassette contains a selective resistance marker, caSAT1, which 
confers resistance to nourseothricin. 
Cap1 and Mrr1 are known to regulate Mdr1 expression, so strains 
SCΔada2CAP1R14A/B and SCΔada2MRR1R34A/B were transformed with a XhoI/SacII 
fragment from plasmid pMDR1G3 (Fig. 16) to introduce the GFP-tagged promoter fusion 
of gene MDR1 in the place of one of the original MDR1 promoters. The newly created 
mutants were named SCΔada2CAP1R14MG3A/B and SCΔada2MRR1R34MG3A/B. 
 
Fig. 16. Structure of the cassette from plasmid pMDR1G3. 
MDR1 promoter (PMDR1) is fused with the GFP protein (GFP***). The ACT1 
transcription termination sequence (ACT1t) was used for a correct termination of the 
GFP transcription. The cassette contains a selective resistance marker, caSAT1, which 
confers resistance to nourseothricin. 
Tac1 is a transcriptional activator of drug-responsive genes including CDR1 and 
CDR2. A GFP-tagged promoter fusion of gene CDR2 was transformed in strains 
PCDR2 GFP*** ACT1t caSAT1 3’CDR2
KpnI SacII
PMDR1 GFP*** ACT1t caSAT1 3’MDR1
XhoI SacII
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SCΔada2TAC1R34A/B. A KpnI/SacII fragment from plasmid pCDR2G3 (Fig. 15) was 
used to produce strains SCΔada2TAC1R34CG3A/B. 
Upc2 is a transcriptional regulator of ergosterol biosynthetic genes and sterol 
uptake, including ERG11. A GFP-tagged promoter fusion of gene ERG11 was transformed 
in strains SCΔada2UPC2R14A/B using a ApaI/SacI fragment from plasmid pERG11G2 
(Fig. 17) to generate strains SCΔada2UPC2R14EG2A and B. 
 
Fig. 17. Structure of the cassette from plasmid pERG11G2. 
ERG11 promoter (PERG11) is fused with the GFP protein (GFP***). The ACT1 
transcription termination sequence (ACT1t) was used for a correct termination of the 
GFP transcription. The cassette contains a selective resistance marker, caSAT1, which 
confers resistance to nourseothricin. 
All the above mentioned GFP-promoter fusions were also transformed in the 
original ΔΔada2 mutants SCADA2M4A/B to create strains SCΔada2MG3A/B, 
SCΔada2CG3A/B, SCΔada2EG2A/B. 
3.2.5 Matched mutants in the SC5314 background 
For each one of the mutants generating from the ΔΔada2 mutants, the matched 
mutant that still contained both ADA2 alleles was required. Those mutants were named in 
the same way as the ΔΔada2 mutants with the difference that the first part of the name, 
indicating the background strain, did not have the “Δada2” part in it. 
With the exception of mutants SCCAP1R14MG3A/B, SCMRR1R34MG3A/B, 
PERG11 GFP*** ACT1t caSAT1 3’ERG11
ApaI SacI
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SCTAC1R34CG3A/B, and SCCG3A/B, the matched SC background mutants (Table 3) 
were already present in the strain collection of Prof. Morschhäuser's group. The eight 
remaining ones were produced in this study in an analogous fashion as for the ΔΔada2 
mutants. SCCAP1R14MG3A/B, and SCMRR1R34MG3A/B were created from strain 
SCCAP1R14A/B, and SCMRR1R34A/B (already present in the strain collection) and 
transforming them with a XhoI/SacII fragment from plasmid pMDR1G3. Strains 
SCCG3A/B, and SCTAC1R34CG3A/B were created transforming a KpnI/SacII fragment 
from plasmid pCDR2G3 into the reference strain SC5314, and SCTAC1R34A/B (already 
present in the strain collection) respectively. 
3.2.6 FACS analysis for determining promoter activity 
Promoter activity was determined by quantifying the fluorescence of the reporter 
strains by Fluorescence-activated Cell Sorter (FACS). All the results were obtained from 
two independently generated reporter strains.  
3.2.6.1 MDR1 promoter activity 
To monitor activation of the MDR1 promoter in response to inducing chemicals 
(hydrogen peroxide and benomyl) or to constitutively active transcription factors, a PMDR1-
GFP reporter fusion was introduced into the knockout ΔΔada2 mutants. In addition, the 
reporter fusion was also added to the reference strain SC5314. Furthermore, the reporter 
fusion was introduced into the ΔΔada2 mutants and SC5314 background strains containing 
hyperactive copies of CAP1 and MRR1. 
The first CAP1 mutant generated on ΔΔada2 background 
(SCΔada2CAP1R14MG3A) showed different phenotypes (growth rate and fluconazole 
susceptibility) from the second one (SCΔada2CAP1R14MG3B). Further analysis indicated 
that the “wrong” mutant was the B strain and not the A strain, so mutant B was excluded 
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from the analysis.  
It was confirmed that Mdr1 activity is not detectable in the wild-type strain SC5314 
in YPD medium, but it could be induced by H2O2 and, even more efficiently by benomyl 
(Fig. 18). Minor differences were observable in the ΔΔada2 knockouts for what concerned 
Mdr1 induction by the used inducing chemicals. In those mutants, benomyl could induce 
Mdr1 activity about two fold as well as in the wild-type, while peroxide had the same 
effect in the ΔΔada2 mutants and in the wild-type. Interestingly, in the only CAP1 mutant 
included in the analysis (SCΔada2CAP1R14MG3A) any GFP expression above the 
background level was barely detectable. In contrast, the hyperactive MRR1 allele, in the 
ΔΔada2 background strains, seemed to have much more effect (twice as much) than in the 
wild-type. 
Of note is the fact that the background fluorescence in all ΔΔada2 mutants is 
slightly higher than in the SC5314 background strains. 
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Fig. 18. Activation of the MDR1 promoter. 
Activation of the MDR1 promoter by H2O2 and benomyl or the hyperactive alleles of 
CAP1 and MRR1 in the wild type SC5314 strain and in the double knock-out mutant 
ΔΔada2. Parental strains and transformants carrying a PMDR1-GFP reporter fusion, and 
the independent derivatives A and B that were rendered homozygous for the CAP1 
and the MRR1 hyperactive alleles, with and without the reporter fusion, were grown as 
described in Materials and Methods. The mean fluorescence of the cells was 
determined by flow cytometry. The results obtained with two independently generated 
strains are shown in each case. The background fluorescence of the parental strains, 
which do not contain the GFP gene, is indicated by the black part in each column. 
3.2.6.2 CDR2 promoter activity 
CDR2 activation by fluphenazine and TAC1 constitutively active allele was 
monitored, both in the wild-type SC5314 background and in the ΔΔada2 mutant. 
Analogously to what has been described for the MDR1 promoter, a PCDR2-GFP reporter 
fusion was introduced in all mutant combinations, SC5314, ΔΔada2 knockouts, SC and 
ΔΔada2 background containing the hyperactive TAC1 allele. 
As shown in Fig. 19, induction of the CDR2 promoter by fluphenazine, both in 
SC5314 and in ΔΔada2 knockout backgrounds, was very efficient, although in ΔΔada2 
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mutants almost three time as much efficient than in the SC5314 background strains. On the 
contrary, the hyperactive TAC1 alleles seem to be less efficient in the ΔΔada2 mutants, 
with a mean fluorescence still detectable but almost half than the one observed in the SC 
background. 
 
Fig. 19. Activation of the CDR2 promoter. 
Activation of the CDR2 promoter by fluphenazine or the hyperactive allele of TAC1 in 
the wild type SC5314 strain and in the double knock-out mutant ΔΔada2. Parental 
strains and transformants carrying a PCDR2-GFP reporter fusion, and the independent 
derivatives A and B that were rendered homozygous for the TAC1 hyperactive allele, 
with and without the reporter fusion, were grown as described in Materials and 
Methods. The mean fluorescence of the cells was determined by flow cytometry. The 
results obtained with two independently generated strains are shown in each case. The 
background fluorescence of the parental strains, which do not contain the GFP gene, 
is indicated by the black part in each column. 
3.2.6.3 ERG11 promoter activity 
ERG11 promoter activity can be induced by chemicals such as ketoconazole or by 
hyperactive alleles of UPC2 transcription factor. ERG11 promoter activity was monitored 
following introduction of a PERG11-GFP promoter fusion in SC5314 and ΔΔada2 
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knockouts, and in mutants containing UPC2 mutated allele which is constitutively active 
on the ERG11 promoter. 
Because ketoconazole requires a longer time to induce promoter activity compared 
to H2O2 and benomyl, in this case incubation time with the inducing chemical was 
increased to 4 hours.  
As shown in Fig. 20, an higher basal fluorescence level was detectable under non 
inducing conditions in the SC5314 background strains compared to the activity of the other 
promoter fusions (PMDR1 and PCDR2). This was even more marked in the ΔΔada2 
background strains, where a very high mean fluorescence, at least five times higher than 
with the other promoter fusions, was detected. Nevertheless, an increased activity of the 
promoter could be observed when ketoconazole was added to the growth medium, or when 
hyperactive alleles of UPC2 transcription factor were present, both in the wild-type 
background and in the ΔΔada2 mutant background. Interestingly, an increased ERG11 
expression is detected even in the absence of any inducing stimuli in the ΔΔada2 mutant. 
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Fig. 20. Activation of the ERG11 promoter. 
Activation of the ERG11 promoter by ketoconazole or the hyperactive allele of UPC2 
in the wild type SC5314 strain and in the double knock-out mutant ΔΔada2. Parental 
strains and transformants carrying a PERG11-GFP reporter fusion, and the independent 
derivatives A and B that were rendered homozygous for the UPC2 hyperactive allele, 
with and without the reporter fusion, were grown as described in Materials and 
Methods. The mean fluorescence of the cells was determined by flow cytometry. The 
results obtained with two independently generated strains are shown in each case. The 
background fluorescence of the parental strains, which do not contain the GFP gene, 
is indicated by the black part in each column. 
3.2.7 Analysis of fluconazole and cerulenin susceptibility by MIC tests 
MIC susceptibility tests were performed in order to evaluate whether the results 
obtained by the FACS analysis could be confirmed by a phenotypic test that directly shows 
a strain‟s susceptibility to fluconazole or cerulenin, compared to its matched wild-type 
background mutant. Fluconazole susceptibility MIC tests (Fig. 21) showed that the double 
ΔΔada2 knockouts (SCADA2M4A/B) were 3 log2 more susceptible to this drug, compared 
to the wild-type SC5314 or even to the heterozygous ΔΔada2 mutant. Complementation of 
one ADA2 allele in the double knockouts re-established the original MIC values, 
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demonstrating that the higher susceptibility of the double ΔΔada2 mutants was due to the 
absence of Ada2 and not to an unspecific mutation that might have occurred during 
transformation.  
The truncated CAP1 hyperactive alleles that have been introduced in the only 
ΔΔada2 mutant SCΔada2CAP1R14A only slightly affected its susceptibility to 
fluconazole, as MIC values were one dilution step higher than those obtained for the 
double ΔΔada2 mutants. When the wild-type SC5314 was considered, MIC values in 
SCCAP1R14A/B were 2 dilutions higher compared to SC5314. 
As already described [47], two hyperactive MRR1 alleles, containing the single C-T 
mutation at position 2047, which results in a proline-serine substitution at position 683, 
confer a marked increased resistance when transformed into the wild-type C. albicans 
SC5314 strain, with MIC values 4 dilutions higher compared to the wild-type. In the 
absence of Ada2 the same behavior was observed, MIC values with hyperactive MRR1 
alleles were 4 dilutions higher compared to the values obtained for the mutants without 
those mutated alleles, although MIC values varied from 0.1 μg/ml to 1.56 μg/ml. 
An analogous behavior was observed in the presence of constitutively active TAC1, 
with MIC values 3 dilutions higher, both in the ΔΔada2 mutants and in the wild-type strain. 
Only in the presence of UPC2 activated alleles a different behavior was observed 
between ΔΔada2 mutants and wild-type. Hyperactive UPC2 alleles did not seem to confer 
any increased resistance in the ΔΔada2 mutants as MIC values remained the same with or 
without them, while in the SC5314 background strain they increased drug resistance by 2 
dilutions.  
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Fig. 21. Fluconazole susceptibility MIC test. 
Wild-type strain SC5314, heterozygous null Δada2 mutants, homozygous null ΔΔada2 
mutants, complementation ada2 mutants, wild-type and double knock-out background 
strains which were rendered homozygous for the hyperactive alleles of CAP1, MRR1, 
TAC1 and UPC2, were tested for fluconazole in a microdilution MIC assay as 
described in Materials and Methods. For each strain two independent transformants 
were tested. For the double knock-out ΔΔada2 mutant containing the hyperactive 
CAP1 allele only one transformant was available. ♦ Strains showing a remarkable 
decrease in growth at a lower drug concentration equivalent to one-step-dilution. 
In addition to fluconazole, the same mutant strains were tested for susceptibility 
towards cerulenin, a substrate for both the ABC transporters Cdr1 and Cdr2 and the major 
facilitator Mdr1 (Fig. 22). 
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Fig. 22. Cerulenin susceptibility MIC test. 
Wild-type strain SC5314, heterozygous null Δada2 mutants, homozygous null ΔΔada2 
mutants, complementation ada2 mutants, wild-type and double knock-out background 
strains which were rendered homozygous for the hyperactive alleles of CAP1, MRR1, 
TAC1 and UPC2, were tested for cerulenin in a microdilution MIC assay as described 
in Materials and Methods. For each strain two independent transformants were tested. 
For the double knock-out ΔΔada2 mutant containing the hyperactive CAP1 allele only 
one transformant was available. ♦ Strains showing a remarkable decrease in growth at 
a lower drug concentration equivalent to one-step-dilution. 
In this case, both heterozygous Δada2 and homozygous knockout ΔΔada2 mutants 
showed the same trend: MIC values against cerulenin were identical to those of the wild-
type SC5314 strain. 
In the presence of CAP1 hyperactive alleles, the only mutant on the ΔΔada2 double 
mutant background analyzed had a MIC value only one dilution step higher compared to 
the strains which did not have the hyperactive allele, in contrast to the SC5314 (1.56 
μg/ml) background strain, where a strong increase in drug resistance could be observed in 
the presence of CAP1 truncated allele, with MIC values 5 dilution steps higher than the 
wild-type (25 μg/ml), confirming what has previously been described [92]. 
If Cap1 seems to require the presence of Ada2 to confer resistance to cerulenin, this 
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does not seem to be true for Mrr1. Indeed, a very high MIC value was observed for mutant 
strains containing the MRR1 hyperactive alleles, both in the ΔΔada2 knockouts and in the 
wild-type, with MIC values of 25 and 50 μg/ml respectively, meaning 5 and 6 dilution 
steps higher than the strains without any constitutively active allele (Fig. 22). 
When TAC1 was analyzed, a minor increase in cerulenin resistance was still 
detectable in ΔΔada2 mutants, one dilution step higher than in the mutant without TAC1 
hyperactive allele, while in the wild-type SC strain, hyperactive allele conferred resistance 
of 3 dilution steps higher (Fig. 22). 
As could be expected, since cerulenin is a target of the efflux pumps and does not 
directly interfere on the ergosterol biosynthesis, only a slight effect was observed in the SC 
background when hyperactive alleles of UPC2 were integrated in its genome. No effect on 
MIC values was observed in the ΔΔada2 mutants. 
3.2.8 Confirmation of ADA2 complementation by spot assay 
Following the destruction of the second ADA2 allele, the obtained mutant strains 
showed a growth defect which was clearly visible when a spot assay was performed. 
The growth rate difference between wild-type or heterozygous Δada2 mutants and 
the homozygous ΔΔada2 mutants was even more pronounced when the strains were grown 
on nourseothricin containing media. Fig. 23 shows the results obtained in a spot assay, 
where the different strains were compared on two different media, the complete rich media, 
YPD agar, and the N10 agar, YPD additioned with 10 μg/ml nourseothricin. The double 
knock-out mutants (SCADA2M4A/B) showed a growth defect, which was even more 
noticeable on the nourseothricin containing medium. While the heterozygous mutants did 
not show a different phenotype compared to the wild-type, the double knock-outs had a 
clear growth defect: on YPD media they grew as smaller colonies and they formed 
colonies only from a starting cell concentration 10 fold higher than the wild-type. This 
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behavior was more evident on N10 plates, since the colonies were formed only starting 
from a cell concentration equal to OD600nm = 10, 10
3
 times higher than the cell 
concentration required to form a colony in the case of SC5314.  
To confirm that the observed phenotype was due to the lack of Ada2 and not to an 
unspecific mutation which could have occurred during the second round of transformation, 
one Ada2 allele was reintroduced in the double mutants SCADA2M4A/B, generating 
strains SCADA2MK2A/B. The wild-type phenotype was restored, the growth rate was 
normal and the nourseothricin sensibility was back to normal levels. 
 
Fig. 23. Spot assay. 
Wild-type strain SC5314, heterozygous Δada2 and homozygous ΔΔada2 knock-out 
deletion mutants and complementation mutants were spotted on nourseothricin 
containing YPD (10 µg/ml – N10) and normal YPD as described in Materials and 
Methods. Picture was taken after 24 h of growth. 
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4 DISCUSSION 
4.1 Differential requirement of the transcription factor Mcm1 for 
activation of the Candida albicans multidrug efflux pump MDR1. 
The transcription factors Mrr1 and Cap1 are both involved in the induction of 
MDR1 expression in response to inducing chemicals; in addition, activating mutations in 
either of the two transcription factors result in constitutive overexpression of the efflux 
pump [7] [47] [50] [92] [93]. However, little is known about how Mrr1 and Cap1 activate 
MDR1 transcription and which additional regulatory factors may be required. In this study 
the role of the MADS box transcription factor Mcm1 has been addressed, which has 
previously been implicated in the regulation of MDR1 expression and was recently shown 
to bind to the MDR1 promoter in vivo [50] [56] [94] [95]. 
Mcm1 can act as both a positive and a negative regulator of transcription [57] [95]. 
Depletion of Mcm1 did not result in constitutive activity of the MDR1 promoter, indicating 
that the role of Mcm1 is not that of a repressor of MDR1 expression in the absence of 
inducing conditions. Moreover, depletion of Mcm1 did not affect the inducibility of the 
MDR1 promoter by H2O2 or the constitutive MDR1 overexpression caused by a 
hyperactive Cap1. On the other hand, benomyl-induced MDR1 expression was reduced, 
but not abolished, following depletion of Mcm1 and a hyperactive Mrr1 could not 
upregulate in the absence of Mcm1. The MDR1 transcripts that were still present after 
Mcm1 depletion in strains expressing the hyperactive Mrr1 may represent mRNAs that 
were produced before Mcm1 depletion and not yet degraded. Alternatively, the cells might 
have contained residual amounts of Mcm1 that were not detectable by western blot 
analysis. These results suggest that the induction of MDR1 expression by H2O2 occurs 
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mainly via activation of Cap1, which acts independently of Mcm1, and the induction by 
benomyl occurs partially via Mrr1, which depends on Mcm1 to activate the MDR1 
promoter, and partially via Cap1. Like H2O2, benomyl causes oxidative stress and activates 
Yap1, the homolog of Cap1 in Saccharomyces cerevisiae [96]. In response to oxidative 
stress, conserved cysteine residues in the C-terminus of Yap1 form disulphide bonds, 
resulting in conformational changes that interrupt the interaction of Yap1 with the nuclear 
export protein Crm1, so that Yap1 can accumulate in the nucleus and activate its target 
genes [97]. In C. albicans, Cap1 activity is also regulated by nuclear-cytoplasmic shuttling 
and mutation of one of the conserved cysteines in Cap1 or removal of the C-terminus 
results in constitutive Cap1 activity [92] [98].  
Based on the results of this and previous studies, the model shown in Fig. 24 
depicts the involvement of Mrr1, Cap1, and Mcm1 in four scenarios in which MDR1 
expression is upregulated.  
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Fig. 24. Model of the role of Cap1, Mrr1 and Mcm1 in MDR1 upregulation. 
Role of the transcription factors Cap1, Mrr1 and Mcm1 in MDR1 upregulation by 
inducing chemicals or gain-of-function mutations in Cap1 and Mrr1. Thinner bent 
arrows indicate reduced MDR1 promoter activity in the absence of the missing 
transcription factor. (A) H2O2 activates Cap1, resulting in accumulation of the 
transcription factor in the nucleus, where it can induce MDR1 expression together with 
Mrr1 in an Mcm1-independent fashion. (B) Benomyl activates Mrr1 and partially also 
Cap1 in an unknown way. When Cap1 is available at the MDR1 promoter (a), Mrr1 
and Cap1 can induce MDR1 expression independently of Mcm1. In the absence of 
Cap1 (b), Mrr1 requires Mcm1 to induce MDR1 expression. (C) A hyperactive form 
of Cap1 (labeled Cap1*) can induce the MDR1 promoter in the absence of inducing 
stimuli and independently of Mcm1 and Mrr1 (a), but full induction requires the 
presence of Mrr1 (b). (D) A hyperactive Mrr1 containing a gain-of-function mutation 
(labeled Mrr1*) can induce the MDR1 promoter independently of Cap1 (which is 
localized in the cytoplasm in the absence of inducing stimuli), but requires the co-
regulator Mcm1.  
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In the presence of H2O2 (Fig. 24A), Cap1 is activated, accumulates in the nucleus, 
and induces MDR1 expression. Under these conditions, Cap1 requires Mrr1 to activate the 
MDR1 promoter, but Mcm1 is dispensable. In the presence of benomyl (Fig. 24B), Cap1 is 
also activated by oxidative stress and can induce MDR1 expression together with Mrr1 
independently of Mcm1 (a). However, MDR1 induction by benomyl can also occur at a 
reduced level in the absence of Cap1 in an Mrr1-dependent fashion, and this requires the 
presence of Mcm1 (b). How benomyl activates Mrr1 is not known. It is possible that Mrr1 
is activated by direct binding of the drug, similar to the zinc cluster transcription factors 
Pdr1 and Pdr3, which regulate efflux pump expression in S. cerevisiae and Candida 
glabrata [99]; however benomyl may also activate Mrr1 in an indirect fashion. The C-
terminally truncated, hyperactive Cap1 can upregulate MDR1 expression even in the 
absence of Mrr1, but not as efficiently as in a wild type background (Fig. 24C). In this 
respect, the hyperactive Cap1 differs from activated wild-type Cap1, which requires Mrr1 
to induce the MDR1 promoter in response to H2O2 or benomyl. However, similar to 
oxidative stress-activated Cap1, the hyperactive Cap1 does not depend on Mcm1 to induce 
MDR1 expression. Finally, a hyperactive Mrr1 can promote MDR1 overexpression 
independently of Cap1, but in this case it requires Mcm1 (Fig. 24D). Altogether, these 
results indicate that Mrr1 can upregulate MDR1 expression in cooperation with either Cap1 
or Mcm1. In response to oxidative stress, Mrr1 cooperates mainly with activated Cap1 to 
induce the MDR1 promoter and Mcm1 is largely dispensable. In the absence of inducers, 
Cap1 remains in the cytoplasm and a hyperactive Mrr1 depends on the presence of Mcm1 
to cause MDR1 overexpression. These observations are in accordance with previous 
findings indicating that deletion of the putative Mcm1 binding sequence (the BRE/MDRE) 
from a truncated MDR1 promoter abolished benomyl-induced or constitutive MDR1 
overexpression [50] [56]. However, deletion of the BRE/MDRE from the full-lenght 
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MDR1 promoter did not affect its constitutive activity in strains that contained gain-of-
function mutations in Mrr1 [47] [51] [56]. The result of the present study, showing that a 
hyperactive Mrr1 requires Mcm1 to mediate MDR1 overexpression, indicates that Mcm1 
can contribute to MDR1 expression in a manner that is independent of its binding site in 
the BRE/MDRE, either by binding to an additional region in the MDR1 promoter or by 
interacting with bound Mrr1 without being directly bound to the DNA. Indeed, a recent 
paper by Askew and coworkers demonstrates that Mcm1 binds to the MDR1 promoter in 
two ways: 1) on its canonical motif independently of any other co-factor; 2) on a non 
canonical motif through Ahr1  [100]. This protein is a DNA binding factor that targets 
promoters regulating several key adhesion genes, and it has also been shown to be 
involved in hyphal growth and virulence. The Ahr1 motif is located upstream of the Mcm1 
motif in a region containing a cis-acting sequence of MDR1  [49] [51]. Therefore, the 
proposed model is that Mcm1 mediates MDR1 overexpression together with hyperactive 
Mrr1 by binding to the Ahr1 motif further upstream, even in the absence of its canonical 
binding motif, the BRE/MDRE. 
4.2 Differential requirement of the transcription factor Ada2 
The transcription factor Ada2 has a central role in cell wall integrity [101] which 
explains the growth defect phenotype in the double knock-out mutant. Higher basal 
autofluorescence of the ΔΔada2 mutants containing GFP protein compared to wild-type 
background strains containing GFP protein can also be explained by the role that Ada2 
occupies in cell wall integrity. It is widely recognized that high cell autofluorescence 
indicates cell death [102] [103]. Ada2 is not an essential protein in Candida albicans, but 
its complete removal induces in the cell a very susceptible state, most likely because of a 
perturbation of the cell wall integrity.  
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It has been showed in previous studies that Ada2 is recruited to at least 200 
promoters upstream of genes involved in different stress-response functions and metabolic 
processes. In particular, Ada2 binds the promoters of several drug transporters, such as 
MDR1, CDR1, CDR4, QDR1, YCF1, FLU1, ORF19.4531, and ORF19.301 as well as the 
phosphatidylinositol transfer gene PDR16 [59]. In this study it was confirmed by MIC 
assay that an increase in sensitivity to fluconazole could be observed in cells lacking 
ADA2. This suggests that Ada2 plays a role in C. albicans azole tolerance, most likely by 
its recruitment as a co-activator by TFs that control the expression of several drug 
transporters. Constitutive activation of the transcriptional regulators of efflux pumps such 
as Tac1, Upc2, Mrr1 or Cap1, have been associated with clinical azole resistance in C. 
albicans [46] [104] [105], and therefore those TFs could use Ada2 as a coactivator to 
activate their targets. 
4.2.1 Role of Ada2 in the activation of MDR1 expression 
As already mentioned, Ada2 recruitment to the promoters of oxidative resistance 
genes is mediated by the transcription factor Cap1. In addition, Ada2 co-occupies together 
with the drug resistance regulator Mrr1 the promoters of core resistance genes involved in 
drug resistance. Sellam and coworkers have shown that Mrr1 and Ada2 cooccupied six 
gene promoters among the eight core resistance genes, including MDR1 [59]. They 
speculated that Ada2, since occupancy of these genes was completely dependent on Mrr1, 
functions as a co-activator for Mrr1. Results obtained in the present study demonstrate that 
Ada2 plays a role in the Mrr1-dependent activation of MDR1 promoter, but it acts more 
like a repressor since its removal leads to a higher MDR1 expression in the presence of an 
hyperactive or a benomyl-activated Mrr1 allele (Fig. 25).  
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Fig. 25. Model of the role of Cap1, Mrr1 and Ada2 in MDR1 upregulation. 
Role of the transcription factors Cap1, Mrr1 and Ada2 in MDR1 upregulation by 
inducing chemicals or gain-of-function mutations. Thicker bent arrows indicate 
increased MDR1 promoter activity in the absence of the missing transcription factor. 
(A) H2O2 activates Cap1, resulting in accumulation of the transcription factor in the 
nucleus, where it can induce MDR1 expression together with Mrr1 in an Ada2-
independent fashion. (B) A hyperactive form of Cap1 (labeled Cap1*) can induce the 
MDR1 promoter in the absence of inducing stimuli but needs the presence of Ada2. 
Mrr1 is dispensable. (C) Ada2 and Mrr1 co-localize on the same region of MDR1 
promoter (a); in the absence of Ada2 both the hyperactive form of Mrr1 (labeled 
Mrr1*) (b) and the Mrr1 activated by the presence of benomyl (c) can induce an even 
higher expression of MDR1. 
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Concerning the role of Ada2 in Cap1 dependent MDR1 expression, results obtained 
in this study demonstrate that hydrogen peroxide-activated Cap1 allele is able to 
completely induce the expression of MDR1 even in the absence of Ada2, while the 
hyperactive allele of Cap1 (although results refer to one single mutant and thus need 
further confirmation) seems to need both Mrr1 and Ada2 on the MDR1 promoter to 
perform its activity of activator. 
4.2.2 Role of Ada2 in the activation of CDR2 expression 
The cis-acting drug-responsive element (DRE), present in the promoters of CDR1 
and CDR2 genes and necessary for their upregulation, contains 5'-CGG-3' triplets that are 
often recognized by transcriptional activators with Zn(2)-Cys(6) fingers. Tac1 TF is the 
main regulator of the expression of those two efflux pumps [41], and Ada2 binds to CDR1 
promoter too [59], but the relationship between Tac1 and Ada2 is not yet known. The 
absence of Ada2 impairs CDR1 inducibility by tunicamycin, therefore in this study it has 
been evaluated if a similar trend could be observed in CDR2 inducibility by hyperactive 
Tac1 or fluphenazine, an inducer of CDR1 and CDR2 expression. The results obtained in 
this study indicate that the resistance regulator Tac1 shares the recruitment of Ada2 on the 
CDR2 promoter: indeed, the absence of Ada2 leads to a reduced expression of CDR2 
induced by the hyperactive form of Tac1 (Fig. 26). An opposite behavior can be observed 
when the expression of CDR2 is induced by the presence of fluphenazine. In the absence of 
the Ada2 TF, fluphenazine has a much more powerful effect on CDR2 expression. 
Therefore, Ada2 has a modulator role, upregulating or down-regulating gene expression in 
response to environmental changes. This aspect of Ada2 activity had already been hinted in 
a previous study published by Jacobson and Pillus [106], where Ada2 is shown to 
participate in both transcriptional repression and activation, in response to nutrient 
signaling. 
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Fig. 26. Model of the role of Tac1 and Ada2 in CDR2 upregulation. 
Role of the transcription factors Tac1 and Ada2 in CDR2 upregulation by inducing 
chemicals or gain-of-function mutations. Thicker or thinner bent arrows indicate 
increased or decreased CDR2 promoter activity in the absence of the missing 
transcription factor respectively. (A) Fluphenazine induces CDR2 expression (a) but in 
the absence of Ada2 this expression is increased (b). (B) A hyperactive form of Tac1 
(labeled Tac1*) can induce the CDR2 promoter in the absence of inducing stimuli (a) 
but needs the presence of Ada2 for a full induction (b). 
4.2.3 Role of Ada2 in the activation of ERG11 expression 
Despite a very high autofluorescence observed in the FACS analysis experiments 
with ΔΔada2 mutants containing a GFP tagged ERG11 promoter, relevant information 
could be obtained. In fact, subtracting the autofluorescence from the mean fluorescence 
values of the GFP containing mutants, a relatively high ERG11 promoter activation can be 
detected, even in the absence of inducing chemicals or hyperactive UPC2 alleles. This 
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could suggest that Ada2 has a repressive effect on the promoter of ERG11. Interestingly, 
both ketoconazole and the hyperactive UPC2 alleles seem, when autofluorescence is 
subtracted from the mean fluorescence, to induce more efficiently in the ΔΔada2 mutant 
than in the wild-type background. These data do not directly reflect the MIC values 
obtained from fluconazole susceptibility tests. UPC2 hyperactive alleles confer fluconazole 
resistance in the wild-type background, but no effect can be detected when the hyperactive 
UPC2 TF is cloned in the ΔΔada2 mutant background. A possible explanation for this 
apparent discrepancy is that the effect of the missing Ada2 TF on the increased basal 
ERG11 expression could be masked by the drastic effects on cell wall integrity which 
indirectly lead to an increase in susceptibility to fluconazole. Alternatively, the overall 
increase in fluorescence could be interpreted as fold increase over background. In this case 
the ERG11 promoter activation in ΔΔada2 mutants results lower than in the wild-type in 
all cases, with or without inducing stimuli. Additional control experiments are therefore 
required to unequivocally confirm either option. In this regard, quantitative qRT-PCR on 
ERG11 transcripts, or the measurement of GFP protein with a specific antibody, although 
semi-quantitative, would bypass auto fluorescence problems. 
4.2.4 Effect of Ada2 absence on fluconazole and cerulenin resistance 
In agreement with previous studies [59] these data confirm that Ada2 removal 
renders Candida albicans more susceptible to fluconazole. In addition, these results 
demonstrate that the removal of Ada2 leads to activation or repression of a certain 
promoter depending on the environmental conditions. This explains why FACS analysis 
does not always strictly correlate with MIC assay results, confirming that fluconazole 
resistance is a multi-factorial event and cannot be explained by the analysis of a single 
gene expression. 
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Since the depletion of Ada2 does not seem to have any detectable effect on 
cerulenin susceptibility, the results obtained from the MIC assays performed with this drug 
are easier to interpret. Cerulenin is a substrate for both the ABC transporters Cdr1 and 
Cdr2 and the major facilitator Mdr1. Hyperactive Cap1 and Tac1 alleles need Ada2 to fully 
activate MDR1 and CDR2 expression respectively and this is reflected in a higher 
susceptibility towards cerulenin when ΔΔada2 mutants containing hyperactive Cap1 or 
Tac1 are analyzed. On the contrary, Mrr1 does not need Ada2 to induce MDR1 expression, 
since Ada2 represses the full activation of MDR1 promoter in the presence of hyperactive 
Mrr1. ΔΔada2 mutants containing hyperactive MRR1 alleles could be expected to have a 
higher cerulenin MIC value. Instead the results obtained showed that the difference in MIC 
value in the SC5314 background and in the ΔΔada2 mutant background is only one 
dilution step. It could therefore be hypothesized that Ada2 depletion has some other 
unknown effect, which hampers Mrr1 contribution to cerulenin resistance. As expected, 
UPC2 hyperactive allele does not have a significant effect on cerulenin resistance, and this 
is consistent with the fact that Upc2 does not have Mdr1, Cdr1 or Cdr2 as targets. 
4.3 Concluding remarks 
Fluconazole resistance in Candida albicans is a multi-factorial event. Depending on 
the inducing conditions and the combination of transcription factors involved, C. albicans 
uses different mechanisms to upregulate expression of the various genes involved in drug 
resistance.  
The present study provides new insights into the functional role of transcription 
factors known to be involved in regulation of core drug resistance genes. 
Future research will be aimed to unravel how each considered transcription factor 
activates its target promoter in order to identify new potential targets for the development 
of novel antifungal strategies. 
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